PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Prog Lipid Res. Author manuscript; available in PMC 2012 April 1.
Published in final edited form as:
PMCID: PMC3062638
NIHMSID: NIHMS278449

Is lipid signaling through cannabinoid 2 receptors part of a protective system?

Abstract

The mammalian body has a highly developed immune system which guards against continuous invading protein attacks and aims at preventing, attenuating or repairing the inflicted damage. It is conceivable that through evolution analogous biological protective systems have been evolved against non-protein attacks. There is emerging evidence that lipid endocannabinoid signaling through cannabinoid 2 (CB2) receptors may represent an example/part of such a protective system/armamentarium. Inflammation/tissue injury triggers rapid elevations in local endocannabinoid levels, which in turn regulate signaling responses in immune and other cells modulating their critical functions. Changes in endocannabinoid levels and/or CB2 receptor expressions have been reported in almost all diseases affecting humans, ranging from cardiovascular, gastrointestinal, liver, kidney, neurodegenerative, psychiatric, bone, skin, auto-immune, lung disorders to pain and cancer, and modulating CB2 receptor activity holds tremendous therapeutic potential in these pathologies. While CB2 receptor activation in general mediates immunosuppressive effects, which limit inflammation and associated tissue injury in large number of pathological conditions, in some disease states activation of the CB2 receptor may enhance or even trigger tissue damage, which will also be discussed alongside the protective actions of the CB2 receptor stimulation with endocannabinoids or synthetic agonists, and the possible biological mechanisms involved in these effects.

Keywords: Endocannabinoids, Cannabinoid 1 and 2 receptors, Disease, Inflammation, Immune function, Disease

1. Introduction

The mammalian body has a highly developed immune system, whose main role is to guard against protein attack and prevent, reduce or repair a possible injury. It is inconceivable that through evolution analogous biological protective systems have not been developed against non-protein attacks. Are there mechanisms through which our body lowers the damage caused by various types of neuronal as well as non-neuronal insults? The answer is of course positive. Through evolution numerous protective mechanisms have been evolved to prevent and limit tissue injury.

We believe that lipid signaling through cannabinoid 2 (CB2) receptors is a part of such a protective machinery and CB2 receptor stimulation leads mostly to sequences of activities of a protective nature. Inflammation/tissue injury triggers rapid elevations in local endocannabinoid levels, which in turn regulate fast signaling responses in immune and other cells modulating their critical functions. Endocannabinoids and endocannabinoid-like molecules acting through the CB2 cannabinoid receptor have been reported to affect a large number of pathological conditions, ranging from cardiovascular [1,2], gastrointestinal [3,4], liver [57], kidney [8,9], lung [10], neurodegenerative [1114] and psychiatric [1520] disorders to pain [21,22], cancer [2326], bone [27,28], reproductive system [2931] and skin pathologies [32] (Fig. 1). This receptor works in conjunction with the immune system and with various other physiological systems. As numerous excellent reviews have been published on the actions of the endocannabinoid system on specific topics, in this Review we aim to summarize some of the protective actions of the CB2 receptor stimulation with endocannabinoids or synthetic agonists, and the possibly biological mechanisms involved in these effects. While CB2 receptor activation in general mediates immunosuppressive effects, which limit inflammation and associated tissue injury in large number of pathological conditions, in some disease states activation of the CB2 receptor may enhance or even trigger tissue damage, which will also be discussed alongside the protective actions.

Fig. 1
Role endocannabinoid-CB2 signaling in various diseases affecting humans. Selected disease conditions are shown in which dysregulation of the endocannabinoid-CB2 signaling is implicated in the pathology. Conversely, in these conditions pharmacological ...

2. The endocannabinoid system and endocannabinoids

The endocannabinoid system is a latecomer to the family of neuromodulators. Looking back, its late discovery was an anomaly. Despite the advances made in the chemistry of cannabinoids, the molecular basis of cannabinoid activity remained enigmatic for several decades. The chemistry of the constituents of the cannabis plant was investigated from the mid 19th century intermittently for almost a century [33], but the main psychoactive constituent, Δ9-tetrahydrocannabinol (THC), was isolated in pure form and its structure was elucidated only in 1964 [34]. Mainly due to its lipophilicity, over the next 2 decades it was assumed that its activity was due to some unspecific effects, comparable to the actions of anesthetics and solvents [33]. Some experimental work presumably gave support to this belief [35]. A further, conceptual, assumption also pointed in the same direction. Both enantiomers of THC were found to be active in some simple physiological assays, although the level of activity differed considerably, the natural (–) enantiomer being much more active than the synthetic (+) enantiomer. As natural active sites of enzymes or receptors are chiral, it is generally accepted that only one enantiomer of an active material will react with them. As both THC enantiomers were found to be active, it was assumed that its action did not involve such an active site [33]. However, in the mid-1980's it was shown that, when well purified, the enantiomers of a very potent analog of THC, namely the (–) enantiomer, HU-210, was nearly 5000 times more potent than the (+) enantiomer, HU-211 [36]. The assumption that both enantiomers were active was in fact due to a technical error, presumably of purification!

In 1988 Howlett's group in St. Louis reported the presence of a specific cannabinoid receptor in the brain [37]. Today it is generally known as the CB1 receptor, which was cloned shortly after this initial discovery [38]. A second receptor, now known as CB2, was identified in rat spleen and was also cloned in 1993 [39]. Although numerous other receptors such as the transient receptor potential cation channel subfamily V member 1 (TRPV1), G protein-coupled receptors 55 and 119 (GPR55 and GPR119) may bind some cannabinoids under certain conditions, they are not yet considered cannabinoid receptors as their specificity for cannabinoids is tenuous [10,4043]. While there is considerable evidence suggesting that targeting TRPV1 receptors has strong therapeutic rational in pain and multiple other disorders [44,45], and recent studies provide support for anandamide being a potential physiological agonist in the brain at these receptors [4648], compelling in vitro or vivo functional evidence on the role of GPR55 and GPR119 in health and disease, as well as on the effects of endocannabinoids/cannabinoids on these targets have been limited by a lack of selective pharmacological tools [40,43]. Surprisingly, by using multiple novel tools, a recent study from GlaxoSmithKline challenged the possibility of GPR55 being the “third” endocannabinoid receptor [43].

The CB1 receptor was originally considered to be mainly a CNS receptor, but it is now known to be present in many tissues and organs and its activation leads to both central and peripheral effects [10,49]. Its best known effect is psychoactivity; its activation and the resulting ‘high’ are the most popular upshot. Its specific effects – in the nervous, cardiovascular, gastrointestinal, reproductive etc. systems – are of paramount importance in vertebrate and invertebrate physiology.

The CB2 receptor has recently been bestowed the title of a ‘cannabinoid receptor with an identity crisis’ [50]. Initially it was presumed to be absent in the central nervous system. High levels of CB2 mRNA were found in the spleen. However, more recently it was found in microglia, particularly during neuroinflammation, which causes activation of the microglia and enhancement of CB2 levels [13,50]. Its presence in neurons [51] is still controversial – hence the ‘identity crisis’. CB2 is coupled to a Gi/o protein receptor and inhibits adenylyl cyclase, which is similarly affected by the CB1 receptor, but the latter can also be coupled with other G proteins such as Gs and Gq/11 [49]. It modulates Ca2+ channels, though less than the CB1 receptor, promotes MAPK activation and ceramide production among many other effects [13,50]. Interestingly, stimulation of CB2 receptors in immune cells after initial decrease in cAMP production may lead to a sustained, more pronounced increase in cAMP levels, which results in suppression of T cell receptor signaling through a cAMP/PKA/Csk/Lck pathway [52].

The first endogenous cannabinoid, arachidonoyl ethanolamide (anandamide, AEA) was isolated in 1992 from porcine brain [53]. A highly potent, centrally active tritium labeled cannabinoid [54], was bound to the CB1 receptor and liposoluble extracts were tested for their ability to replace it. An active extract was further purified by silica gel chromatography to yield minute amounts of an active constituent, whose structure was determined by physical methods and by comparison with synthetic material. A second endocannabinoid, 2-arachidonoyl glycerol (2-AG), was identified a few years later by the same method using a peripheral organ [55]. Independently, it was also identified in brain [56]. These two endocannabinoids have been investigated in great detail [10,49,57]. Numerous other endocannabinoids and related endogenous substances have also been identified, but their activities have not been investigated to the same extent [45,58].

Contrary to most neurotransmitters, anandamide and 2-AG are formed postsynaptically mostly when and where needed [10,41,57]. Their formation and metabolism have been investigated in considerable detail as these processes determine the levels of the endocannabinoids and their physiological activities. The best known enzymes involved are fatty acid amine hydrolase (FAAH), diacyl glycerol lipase (DAGL), monoacyl glycerol lipase (MAGL). Some of these enzymes exist in several forms and their levels of activity vary in different tissues [5963]. Examples of prototypical endogeneous/exogenous cannabinoid receptor ligands (mentioned in this review) with various degrees of activities at CB2 receptors are presented in the Table 1. For the structures of these ligands and numerous recently developed another ones we would like to refer readers to several recent overviews [6469].

Table 1
Prototypical cannabinoid receptor ligands used in overviewed studies with effects on CB2.

3. CB2 receptors and endocannabinoids in health and disease

The CB2 receptor was previously considered to be expressed predominantly in immune and hematopoietic cells. Indeed, CB2 receptors are expressed in almost all human peripheral blood immune cells with the following rank order of mRNA levels: B cells > NK cells > monocytes > PMNs > T cells, respectively (overviewed in [76]). The CB receptor expression in immune cells can be influenced by various inflammatory, e.g. bacterial lipopolysaccharide (LPS), and other triggers activating these cells, and may therefore largely be dependent on the experimental conditions [76]. Interestingly, inflammatory stimuli may also trigger increased production of endocannabinoids in immune cells (e.g. macrophages, peripheral-blood mononuclear cells and dendritic cells) via activation of various biosynthetic pathways, and/or by reducing expression of the metabolic enzyme(s) responsible for the degradation (overviewed in [77,78]). Earlier studies investigated the immunomodulatory effects of THC (a ligand for both CB1 and CB2 receptors) and other natural or synthetic cannabinoids, in mice and/or rats in vivo or in immune cells cultured from humans. Overall, these studies have shown suppressive effects of cannabinoid ligands on B, T, and NK cells, and macrophages, which most likely involve both CB1 and CB2 receptor-dependent and -independent mechanisms [76,77,79]. Recent studies have also revealed that endocannabinoids may exert important effects on immune functions by modulating T and B lymphocytes proliferation and apoptosis, inflammatory cytokine production and immune cell activation by inflammatory stimuli (e.g. LPS), macrophage-mediated killing of sensitized cells, chemotaxis and inflammatory cell migration, among many others [76,77,80] (Fig. 2). However, these effects (mostly, but not always inhibitory) were largely influenced by the endocannabinoid or synthetic agonist/antagonist, trigger/condition, and cell type used [76,77,81,82]. Similar context and experimental condition-dependent effects of endocannabinoids or synthetic analogs have been reported on microglia activation and migration [81]. Furthermore, cannabinoids may also modulate inducible nitric oxide synthase expression and nitric oxide and reactive oxygen species production in immune cells, which play important role against invading pathogens, as well as in modulating inflammatory response [83]. Endocannabinoids and CB2 receptors have also been implicated in hematopoietic stem and progenitor cell mobilization [84], with potential implication for bone marrow transplantation. Recent studies have also identified low level of CB2 receptor expression in specific regions of the brain [51,85], spinal cord and dorsal root ganglia [21,22,86], neurons in the myenteric and submucosal plexus of the enteric nervous system [8789], colonic epithelial cells [90], bone [27,28,91], myocardium or cardiomyocytes [9294], human vascular smooth muscle [95], activated hepatic stellate cells [5,96], mouse and human exocrine and endocrine pancreas [97101], and endothelial cells of various origins [2,102,103], and in reproductive organs/cells [30,104] and in various human tumors [23] (Fig. 2).

Fig. 2
Cannabinoid 2 receptor (CB2) expression and its known cellular functions. CB2 receptors are most abundantly expressed in cells of the immune system and in cells of immune origin. In these cells CB2 receptors mostly mediate immunosuppressive effects. CB ...

Despite the presence of low level of CB2 receptors, endocannabinoids and their metabolizing enzymes in cardiovascular, gastrointestinal, bone, various neuronal, liver tissues/cells, CB2 receptors appear to play limited, if any role in normal physiological regulation of these organ systems, which is also supported by the absence of obvious pathological alterations in normal CB2 receptors knockout mice [82]. This situation can be different (at least in mice) in male reproductive organs where CB2 receptors are abundantly expressed and may possibly modulate sperm cell differentiation (spermatogenesis) [31], likewise during the development of age-related trabecular bone loss and trabecular expansion [105].

However, under various pathological conditions/disease states the expression of CB2 receptors can be markedly upregulated in affected tissues/cells, which is often accompanied by elevated endocannabinoid levels as a part of the inflammatory response/tissue injury; some of these selected pathologies and related CB2 mediated effect are summarized in Table 2 and Figs. 13.

Fig. 3
Therapeutic targets of cannabinoid 2 receptor (CB2) modulation in inflammation and tissue injury. Endothelial cell activation and endothelial dysfunction is an early event inflicted by any kind of tissue injury/insult. Activated endothelial cells release ...
Table 2
Proposed role of endocannabinoid-CB2 receptor signaling in selected diseases.

4. Effects of CB2 receptor modulation in disease states

The significance of CB2 receptor activation in the above mentioned immunomodulatory effects of endocannabinoids and of various cannabinergic ligands is now becoming increasingly recognized, and most likely these effects are largely responsible for the anti-inflammatory properties of endogenous or synthetic ligands observed in a multitude of disparate diseases and pathological conditions, ranging from atherosclerosis, myocardial infarction, stroke, inflammatory pain, gastrointestinal inflammatory, autoimmune and neurodegenerative disorders, to hepatic ischemia/reperfusion injury, inflammation and fibrosis, kidney and bone disorders and cancer, which will be reviewed below briefly (Fig. 1 and Table 2).

4.1. Cardiovascular disease

Cannabinoids and their endogenous and synthetic analogs, through activation of cardiovascular CB1 and other receptors, exert a variety of complex hemodynamic effects (mostly resulting in decreased blood pressure and myocardial contractility) both in vivo and in vitro involving modulation of autonomic outflow, as well as direct effects on the myocardium and the vasculature, the discussion of which is beyond the scope of this synopsis [10,213]. In contrast, activation of cardiovascular CB2 receptors is devoid of adverse hemodynamic consequences. Despite the presence of functional cannabinoid receptors, endocannabinoids and their metabolizing enzyme in cardiovascular tissues/cells, the endocannabinoid system appears to play limited role in normal cardiovascular regulation under physiological conditions, which is also supported by the normal blood pressure and myocardial contractility and/or baroreflex sensitivity of CB1, CB2 and FAAH knockout mice [10].

In many pathological conditions, such as heart failure, shock, advanced liver cirrhosis, the endocannabinoid system may become overactivated and may contribute to hypotension/cardiodepression through cardiovascular CB1 receptors (overviewed in [1,10]). Tonic activation of CB1 receptors by endocannabinoids may serve as a compensatory mechanism in hypertension [1,214] and may contribute to cardiovascular risk factors in obesity/metabolic syndrome and diabetes, such as plasma lipid alterations, abdominal obesity, hepatic steatosis, insulin and leptin resistance [215217]. CB1 receptor signaling may also promote disease progression in heart failure [92,93,218] and atherosclerosis [117,219,220].

In contrast, CB2 activation in human coronary endothelial and different inflammatory cells (e.g. neutrophils, monocytes, etc.) attenuates the TNF-α or other triggers-induced endothelial inflammatory response, chemotaxis and adhesion of inflammatory cells to the activated endothelium, and the subsequent release of a variety of proinflammatory mediators [102,115], crucial events implicated in the initiation and progression of atherosclerosis and restenosis, as well as in mediating reperfusion-induced tissue injury [221]. CB2 receptor activation may also attenuate the TNF-α-induced human coronary artery smooth muscle cell proliferation [95]. Despite the low levels of CB2 receptors expressed in the myocardium and cardiomyocytes [92,94,108], which can be upregulated in heart failure [125], recent studies have implicated this receptor in cardioprotection [94,108,109]. However, its precise role in cardiomyocyte signaling is still largely unexplored.

4.1.1. Myocardial ischemia/reperfusion (I/R), preconditioning, and stroke

Ischemia followed by reperfusion is a pivotal mechanism of tissue injury in myocardial infarction, stroke, organ transplantation, and during vascular surgeries. Endocannabinoids overproduced during various forms of ischemia/reperfusion (I/R) injury have been proposed to protect against myocardial ischemia/reperfusion injury and to contribute to the ischemic preconditioning effect of endotoxin, heat stress, or brief periods of ischemia [107,222], while these lipid mediators (as mentioned above) may also mediate the cardiovascular dysfunction in these pathologies [1,10]. In initial reports, the weight of the evidence for endocannabinoid involvement was limited by the lack of use of selective ligands and/or cannabinoid receptor deficient animal models, and by the absence of direct quantification of tissue endocannabinoid levels and the use of ex vivo models, in which the key immunomodulatory effects of cannabinoids could not be determined. Recent studies using pre-clinical rodent models of myocardial [106,108,109], cerebral [73,121,124] and hepatic [103,131] I/R injury support an important role of endocannabinoids acting via CB2 receptors in protection against tissue damage triggered by overproduced reactive oxygen and nitrogen species generation during reperfusion [107].

In these models of injury the beneficial effect of CB2 receptor activation by selective synthetic ligands, such as JWH-133 and HU-308, was largely attributed to decreased endothelial cell activation and suppression of the acute inflammatory response as reflected in attenuated expression of adhesion molecules, secretion of chemokines, leukocyte chemotaxis, rolling, adhesion to endothelium, activation and transendothelial migration and interrelated oxidative/nitrosative stress associated with reperfusion damage (overviewed in [107]). Importantly, it was also demonstrated that CB2 receptor knockout mice had increased reperfusion damage, implying a protective role of the endocannabinoid signaling mediated through these receptors. Some of these studies also proposed that CB2 receptor activation may afford direct protection in parenchyma cells such as in cardiomyocytes [108,109], which needs to be confirmed in the future. Collectively, the endocannabinoid system appears to protect against various forms of I/R injury via activation of CB2 receptors located both on endothelial and inflammatory cells, and perhaps also on some parenchyma cells (e.g. cardiomyocytes), and CB2 receptor agonists may represent a protective strategy to attenuate reperfusion injury. For more detailed overviews see [2,223].

4.1.2. Heart failure, cardiomyopathy, septic shock

While there is considerable evidence that endocannabinoids are overproduced in various forms of shock, heart failure and cardiomyopathy and may mediate detrimental effects via CB1 receptor signaling in endothelial cells and cardiomyocytes, relatively little is known on the role of CB2 signaling in these pathological conditions [2,223].

A recent interesting study demonstrated that patients suffering from chronic heart failure exhibited a shift of the myocardial CB1-CB2 receptor ratio towards marked overexpression of CB2 receptors combined with significantly elevated peripheral blood levels of endocannabinoids indicating an activation of the endocannabinoid system [125]. As already mentioned above, the CB2 agonist JWH-133 protected against I/R-induced cardiomyopathy [109] and administration of JWH-133 to cirrhotic rats with ascites significantly improved mean arterial pressure, decreased the inflammatory infiltrate, reduced the number of activated stellate cells, increased apoptosis in nonparenchymal cells located in the margin of the septa, and decreased fibrosis compared with cirrhotic rats treated with vehicle [141]. Since the hepatic endocannabinoid levels directly correlate with degree of liver injury and inflammation [131], it is most likely that the CB2 agonist, by attenuating liver inflammation, also decreased the endocannabinoid levels, thereby resulting in less endocannabinoid-mediated hypotension through the activation of cardiovascular CB1 receptors in the above mentioned study. This is also supported by the fact that CB2 agonist administration did not produce significant hemodynamic effects in normal rodents [131].

Two studies investigating the role of CB2 receptors in a mouse model of bacterial sepsis induced by cecal ligation and puncture yielded opposite results. While in one study CB2 receptor knockout mice showed decreased survival as compared to wild-type mice [129], the other study demonstrated increased survival of knockouts exposed to bacterial sepsis and decreased bacterial load compared to wild types [128]. Notably, these studies used CB2 knockout mice on different background, which may, at least in part, explain the discrepancy in the results. It is also important to note that CB2 receptor activation is generally recognized as an immunosuppressive effect, which protects against overwhelming inflammation in sterile models of tissue injury. However, suppression of the immune system in the presence of live bacteria or other pathogens can promote growth of these pathogens and consequent tissue injury, which is often the reason why many drugs, which are effective in preclinical shock models of sterile inflammation, fail in human sepsis trials. Nevertheless, further studies investigating the role of CB2 receptors in various forms of sepsis and infections with live pathogens are warranted.

4.1.3. Atherosclerosis and restenosis

Proinflammatory cytokines such as TNF-α and bacterial endotoxin(s) are key mediators in the development of atherosclerosis, which induce nuclear factor kappa B (NF-κB)-dependent up-regulation of adhesion molecules and chemokines (e.g. monocyte chemoattractant protein, MCP-1) in endothelial cells promoting recruitment and increased adhesion of monocytes to the activated endothelium followed by their transendothelial migration. These cells also release factors that promote smooth muscle cell proliferation and synthesize extracellular matrix, which also play important role in the development of vascular remodeling that occurs during restenosis (reocclusion of the vessel) in patients who undergo vascular surgery. Synthetic and endogenous cannabinoids have been reported in a context-dependent manner to either inhibit chemokine-induced chemotaxis of various cell types or induce immune cell migration in vitro, at least in part through the activation of CB1/2 receptors, which raises the possibility that they may either attenuate or promote inflammation by influencing recruitment of immune cells to inflammatory sites [2,81]. In vivo, CB2 receptor activation may reduce inflammation by interfering with the action of chemoattractants as demonstrated in studies of ischemia–reperfusion injury and in vitro in human monocytes treated with the synthetic CB2 agonist [2].

CB1/2 receptor-expressing immune cells, endocannabinoids, and their metabolizing enzymes are present both in human and mouse atherosclerotic plaques [2,111,113,117], however the activation of these receptors may exert opposing effects on the disease progression [220]. In a mouse model of atherosclerosis (ApoE –/– mice fed on high fat diet) oral administration of THC resulted in significant inhibition of plaque development in a CB2-dependent fashion, which involved reduced lesional macrophage infiltration, as well as attenuated proliferation and interferon-γ release by splenocytes isolated from THC-treated mice [113]. Using a different cannabinoid ligand in the same in vivo model, another study concluded that the beneficial effects of CB2 activation was due to the attenuation of the expression of adhesion molecules VCAM-1, ICAM-1, and P-selectin, which led to reduced macrophage adhesion and infiltration [114], a concept initially proposed by Rajesh et al. demonstrating that CB2 stimulation attenuated the TNF-α-induced NF-κB and RhoA activation, ICAM-1 and VCAM-1 upregulation, MCP-1/CCL2 release in human coronary artery endothelial cells, as well as transendothelial migration and adhesion of monocytes [102]. An important role of CB2 receptors was also implicated in inflammation-induced proliferation and migration of human coronary artery smooth muscle cells [95], processes crucially involved in the pathogenesis of both atherosclerosis and restenosis. An interesting recent study found that CB1 and CB2 receptor activation may differentially regulate reactive oxygen species production and inflammatory signaling in macrophages [224], which is also supported by recent in vivo studies in model of nephropathy [8,9].

Oxidized LDL is a recognized trigger for atherosclerosis, which accumulates in macrophages within atherosclerotic lesions, resulting in foam cell formation. The ability of oxidized LDL to trigger macrophage apoptosis plays significant role in atherosclerotic plaque stability and the progression of disease. This apoptosis rate was significantly reduced in peritoneal macrophages from CB2 knockout mice as compared to wild type animals, involving Akt survival pathway in CB2-mediated signaling [225]. Further supporting a complex role of CB2 receptors in atherosclerosis a recent study demonstrated that CB2 receptor deficiency affected atherogenesis in Ldlr-null mice by increasing lesional macrophage and SMC content, reducing lesional apoptosis and altering extracellular matrix components, in part, by upregulating matrix metalloproteinase 9 [226].

Despite the above mentioned exciting pre-clinical reports, a recent large case-control study enrolling 1968 individuals addressing the involvement of the gene encoding CB2, CNR2, in the development of myocardial infarction and several cardiovascular risk factors (e.g. obesity, hypertension, hypercholesterolemia and diabetes mellitus) was not able to find any association of the investigated risk factors with the 13 investigated single nucleotide polymorphisms in the CNR2 gene [227]. Nevertheless, further studies are warranted to explore the role of CB2 receptors in cardiovascular disease.

4.2. Liver disease (hepatitis, fibrosis, cirrhosis) and its complications (cirrhotic cardiomyopathy and encephalopathy)

The levels of endocannabinoids and their metabolizing enzymes in the normal liver are comparable to those observed in brain; in both, however, the expression of cannabinoid receptors is very low under physiological conditions. In various liver diseases and their complications, such as hepatitis [133], nonalcoholic fatty liver disease [135], drug-induced toxicity [228], hepatic I/R injury [7,103,131], liver fibrosis and cirrhosis [5,140,141,229], cirrhotic cardiomyopathy and hepatic encephalopathy [139,142,144,146,148,230] dysregulation of the endocannabinoid system (mostly increased levels of endocannabinoid and/or CB1/2 receptors) have been reported [231] (Table 2 and Fig. 1). The most likely sources of CB2 receptors in the normal liver are the resident macrophages (Kupffer cells) [232], endothelial and hepatic stellate cells, while under pathological conditions overexpression of CB2 receptors may also be prominent in hepatocytes and originate from infiltrating inflammatory cells [57]. While CB2 receptor activation in hepatic stellate cells mediates apoptosis and antifibrotic effects [6,96,233], its activation in Kupffer, endothelial and inflammatory cells most likely attenuates inflammation and reactive oxygen and nitrogen species generation associated with hepatic I/R as well as other liver pathologies [7,107]. Selective CB2 receptor agonists administered prior to experimental hepatic ischemia or right after it, attenuated the I/R-induced rise in serum transaminases by decreasing inflammatory cell infiltration, tissue and serum levels of proinflammatory cytokines/chemokines, hepatic lipid peroxidation, and expression of the adhesion molecule ICAM-1 [103,131]. CB2 receptor activation also attenuated the extent of the histological damage and PMN cell infiltration 1 day following the ischemic insult, and CB2–/– mice developed aggravated I/R-induced tissue damage and proinflammatory phenotype in agreement with the protective role of CB2 receptor activation [103,131]. I/R, but not ischemia alone, triggered marked increases in the hepatic levels of endocannabinoids AEA and 2-AG, which originated from hepatocytes, Kupffer and endothelial cells, and positively correlated with the degree of tissue injury and serum inflammatory cytokine and chemokine levels [131]. CB2 receptor activation may also be protective against autoimmune hepatitis [234] and a beneficial effect of such activation in liver injury and regeneration has also been reported [131,145].

Although substantial evidence (briefly reviewed above) supports an important role for the endocannabinoid system and CB2 receptors in modulating inflammatory response and tissue injury in a variety of liver disorders, the exact mechanisms and cellular targets are still largely enigmatic. Additional studies should also address how the endocannabinoid system interacts with immune cells representing the innate immune system (e.g. natural killer cells, gamma delta T cells, and Kupffer cells), which play a pivotal role not only in the host defenses against invading microorganisms and tumor formation, but also in the pathogenesis of various inflammatory liver diseases. Various known polymorphisms of the CB1/2 receptors should also be closely examined and correlated with liver disease severity. Furthermore, fundamental questions regarding the contrasting roles of CB1 and CB2 receptors and endocannabinoids in various liver pathologies (extensively reviewed recently by [5,217,235237]) should also be answered, to devise clinically meaningful cannabinoid-based medicines for liver disease.

4.3. Gastrointestinal (inflammatory bowel disease) and kidney disorders, pancreatitis

CB2 receptor expression or immunoreactivity were found on colonic epithelial cells in mice, but not in rats, under baseline conditions, and CB2 receptor expression was enhanced by the presence of a protective probiotic bacterium (Lactobacillus acidophilus) in mouse, rat and human colonic epithelium cells [90]. Immune cells of the gut also express CB2 receptors. These receptors, as well as tissue endocannabinoid levels can be enhanced in active inflammatory diseases [4]. The expression of the CB2 in the colonic mucosa is still controversial [88,150], and intriguingly CB2 receptor expression was also reported on neurons of the submucosal and myenteric plexuses of the enteric nervous system both in rats and humans [87,89]. There is also some evidence [4,238] substantiating a possibly neuromodulatory role of CB2 receptors in enteric neurotransmission, but overall studies support a role of CB2 receptors in gut motility only in the stomach, particularly in certain pathophysiological states [4,238].

In experimental models of intestinal inflammation induced by various chemical irritants [151153] an increase in the CB2 receptor expression was reported in inflamed gut, and CB2 agonists (JWH-133, AM1241) attenuated the colitis in wild type, but not in CB2 knockout mice, which was exacerbated by a CB2 antagonist AM630. Blockade of the endocannabinoid degrading enzyme FAAH with URB597 or the putative anandamide transporter with VDM11 had anti-inflammatory effect, which could be abolished by CB2 receptor deficiency, further supporting a protective role for the CB2 receptor activation in experimental colitis [152]. CB2 receptors may also play some role in the modulation of the unpleasant visceral sensations (e.g. nausea, pain) in states of gastrointestinal irritation as reviewed recently [4,238], and by controlling gastrointestinal inflammation (a major risk for bowel cancer) may also modulate cancer risk and/or growth.

Michalski et al. [98] have investigated the functional involvement of the endocannabinoid system in modulation of pancreatic inflammation, such as acute pancreatitis. They found an upregulation of cannabinoid receptors and elevated levels of endocannabinoids in the pancreas of patients with acute pancreatitis. They also demonstrated that low doses of HU-210, a potent synthetic agonist at CB1 and CB2 receptors, abolished abdominal pain associated with pancreatitis and reduced inflammation and decreased tissue pathology in mice without producing central, adverse effects [98]. Antagonists at CB1/2 receptors were effective in reversing HU-210-induced antinociception, whereas a combination of CB1- and CB2-antagonists was required to block the anti-inflammatory effects of HU-210 in pancreatitis [98]. In a follow-up study an important role of the endocannabinoid system in chronic pancreatitis was also revealed [99], and a recent study proposed an opposing time-dependent effects of endocannabinoids and CB1/2 receptors on the course of the development of acute pancreatitis [101].

A functional endocannabinoid system also exists in the kidney [8,9,239], which can be activated during kidney injury [8,9]. CB2 receptor activation with a selective receptor agonist attenuates the kidney dysfunction and nephropathy induced by the widely used chemotherapeutic drug cisplatin [8]. The mechanism of the CB2 protection involves not only attenuation of the cisplatin triggered marked inflammatory response in the kidney (chemokine secretion and signaling by MCP-1, MIPs), endothelial cell activation (adhesion molecule expression), inflammatory cell infiltration, TNF-α and IL-1β levels, but also decrease in the expression of the reactive oxygen species (ROS)-generating NADPH oxidase enzyme isoforms NOX4, NOX2, and NOX1, and the consequent renal oxidative stress, alongside with the attenuation of the cisplatin-induced increased NF-κB-dependent iNOS expression and nitrative stress in the kidneys culminating in apoptotic and necrotic cell death [8]. Furthermore, the cisplatin-induced kidney inflammation, oxidative/nitrosative stress, cell death and dysfunction were enhanced in CB2 –/– mice compared to their wild-type CB2+/+ littermates, suggesting that the endocannabinoid system may exert protective effects via tonic activation of CB2 receptors, similar to the effects reported in models of ischemic–reperfusion injury and neuroinflammatory disorders discussed in other parts. In contrast, CB1 receptor activation appears to exert opposing effects in nephropathy models [9,240].

4.4. Bone disorders

Bones, like all other body tissues, undergo substantial changes throughout life. Initially there is a rapid phase, when bone formation and bone resorption compensate each other. It is followed by a steady-state bone growth phase. Finally an imbalanced age-related bone loss may occur [27,28,241]. Remodeling cycles are observed throughout life. They are initiated by a rapid resorption by osteoclast cells, derived from monocytes, followed by slower bone formation by osteoblast cells. Imbalance in bone remodeling may lead to osteoporosis, a common degenerative disease in developed societies. Weakening of the skeleton and increased fracture risk, primarily in females, may be due to a net increase in bone resorption.

Osteoblasts are mostly regulated by bone morphogenetic proteins. Control of osteoclast formation and activity is governed by numerous factors such as macrophage colony-stimulating factor, receptor activator of NF-kB ligand (RANKL), osteoprotegerin, and interleukin 6. Low levels of gonadal hormones in females and males also cause bone loss. Additional factors such as parathyroid hormone, leptin, calcitonin, insulin-like growth factor I, and neuropetide Y are also involved in the control of bone formation [27,28,241]. In osteoclasts, CB1 is barely expressed, however the levels of CB2 mRNA transcripts are high [105,155]. In vivo, CB2 protein is present in trabecular osteoblasts [242], as well as in osteoclasts [105].

2-AG affects osteoblasts directly by binding to CB2 [105,243]. DAGLalpha, one of the enzymes involved in 2-AG biosynthesis, is expressed in bone-lining cells and in osteoblats, while DAGLbeta, the second major enzyme involved in this process, was found in both osteoblasts and in osteoclasts [243]. Interestingly, oleoyl serine (an endocannabinoid-like compound which does not bind to either the CB1 or the CB2 receptors) has recently been described in bone. It increased bone formation and lowered bone resorption in a mouse osteoporosis model induced by estrogen depletion in ovariectomized animals [156].

Rossi et al. [244] have provided evidence for the role of CB2 receptors as negative regulators of human osteoclast activity, as well as on the role of TRPV1 receptor in upregulation of CB2 receptor expression in human osteoclasts obtained from women with osteoporosis; in these cells the role of the endocannabinoid system was also addressed [245].

During their first 2–3 months of life, CB2–/– mice reach a normal peak trabecular bone mass, but later an age-related bone loss is noted [105]. CB2–/– mice have a high bone turnover with increases in both bone resorption and formation. However, ultimately a net negative balance is reached with age [105]. These effects are somewhat similar to human postmenopausal osteoporosis.

Karsak et al. [154] have examined the contribution of cannabinoid receptors to the regulation of bone mass in humans by investigating in osteoporotic patients the polymorphisms in loci, encoding the CB1 and the CB2 receptors. While they found no significant association of the CB1-coding exon with the osteoporosis phenotype, they noted that a common variant of the CB2 receptor contributes to osteoporosis concluding that CNR2 polymorphisms are important genetic risk factors for osteoporosis. Related observations were also published by a Japanese group [246]. The studies by both groups suggest that diagnostic measures to identify osteoporosis-susceptible individuals can be developed based on polymorphisms in CNR2.

As CB2 receptor activation does not lead to psychoactive effects, and in view of the results summarized above, Bab's group assumed that CB2-specific ligands could prevent and/or rescue bone loss, without the occurrence of side effects. Indeed, in the above mentioned mouse osteoporosis model in ovariectomized animals, they found that the specific non-psychoactive CB2 agonist HU-308 [178], significantly attenuated bone loss in both ‘preventive’ [105] or ‘rescue’ protocols [91]. In the preventive approach, the administration of HU-308 was started immediately after ovariectomy. In the ‘rescue’ protocol the drug was given (daily for 4–6 weeks) starting 6 weeks after ovariectomy, when very significant bone loss had occurred. This treatment led to potent inhibition of bone resorption and stimulation of bone formation. These results strongly indicate that CB2 agonists may become both antiresorptive and anabolic drugs for osteoporosis [27,28,91].

4.5. Neurodegenerative disorders (multiple sclerosis, Parkinson's, Huntington's, and Alzheimer's diseases, amyotrophic lateral sclerosis) and pain

A common feature of acute or chronic neurodegenerative diseases, such as multiple sclerosis (MS), Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS) is the presence of oxidative and nitrosative/nitrative stress coupled with inflammation of various degrees [83]. Oxidative stress, inflammation, excitotoxicity, mitochondrial dysfunction, and hereditary and environmental factors have all been implicated in the neuronal dysfunction and death contributing to the pathogenesis of these disorders. Oxidative stress appears to provide a key link between environmental factors such as exposure to herbicides, pesticides, and heavy metals with endogenous and genetic risk factors in the pathogenic mechanisms of neurodegeneration (e.g. in Parkinson's disease) [83]. Oxidative/nitrative stress may also contribute to the disruption of the integrity of the blood–brain barrier and trigger reactive changes in glial elements (e.g. astrocytes and microglia represented by resident macrophage like cells in the brain and spinal cord) [83]. The disruption of the blood–brain barrier facilitates the penetration of various toxins and inflammatory cells to the site of brain injury further propagating damage which eventually leads to irreversible degeneration.

Dysregulation of the endocannabinoid system has been reported in virtually all of the above mentioned forms of acute (e.g. traumatic brain injury, stroke, and epilepsy) or chronic neurodegenerative disorders, such as MS, Parkinson's, Huntington's and Alzheimer's diseases, HIV-associated dementia, and ALS (reviewed by [10,11,173175]). This was mostly reflected by time- and region-dependent increased or decreased endocannabinoid content in the lesions and/or in the cerebrospinal fluids of diseased animals or humans and/or altered cannabinoid receptor expressions in the diseased tissues (reviewed in: [10,11,63,173175]). Earlier studies proposed that endocannabinoids or plant-derived cannabinoids are neuroprotective agents in the CNS [247249], and this neuro-protection involves: (a) attenuation of excitatory glutamatergic transmissions and modulation of synaptic plasticity via presynaptic CB1 receptors; (b) modulation of excitability and calcium homeostasis via effects on Na+, Ca2+, K+ channels, N-methyl d-aspartate (NMDA) receptors, intracellular Ca2+ stores and gap junctions; (c) CB1 receptor-mediated hypothermia; (d) antioxidant properties of cannabinoids; (e) modulation of immune responses and the release of inflammatory cytokines/chemokines by CB1, CB2, and non-CB1/CB2 receptors on neurons, astrocytes, microglia, macrophages, neutrophils and lymphocytes [10]. However, numerous recent studies have also suggested that endocannabinoids through the activation of CB1 receptors may also promote tissue injury and neurodegeneration (for example in stroke and other forms of I/R injury) [107,174,175], and many of the previously described protective effects of various synthetic CB1 ligands were in fact attributable to centrally-mediated hypothermia and/or receptor-independent antioxidant/anti-inflammatory effects of the compounds [107].

Since functional CB2 receptors are predominantly expressed on activated microglia and cells of immune origin in the brain and spinal cord (these cells are progressively present in pathological lesions associated with traumatic brain injury, stroke, MS, Parkinson's, Huntington's and Alzheimer's diseases, and ALS), their modulation by selective CB2 receptor ligands may represent an interesting therapeutically exploitable possibility [165,174,175,250]. However, the achievement of this goal is largely complicated by the fact that depending on the particular disease type and its stage/progression, the inflammation by itself can be both beneficial and detrimental. Nonetheless, several lines of recent evidence have suggested an important role for CB2 receptors in regulating central inflammatory response, neurodegeneration and neurogenesis. Firstly, increased immunoreactivity associated with microglial activation and/or immune cell infiltration has been reported in brain lesions of patients with MS [158], Alzheimer's disease [157,159,251], Down's syndrome [252], and in experimental animals exposed to neurotoxin or ischemia [164,253], as well as in mice with experimental autoimmune encephalomyelitis (EAE) [160], a model of MS. Secondly, CB2 receptor agonists exert beneficial effects in pre-clinical models of stroke [73,121,254], spinal cord injury [123], Parkinson's disease (MPTP toxicity) [164], MS [161], Huntington's disease (malonate toxicity) [168], amyotrophic lateral sclerosis (hSOD1G93A transgenic mice) [162,163], and Alzheimer's disease [159]. Thirdly, CB2–/– mice have larger cerebral injury and dysfunction following cerebral I/R [121], and they are more sensitive to the toxic effects of neurotoxin MPTP [164], and have more inflammation in an experimental model of MS [161]. Finally, CB2 receptor agonists promote neural progenitor proliferation, suggesting that this receptor may also play an important role in the neurogenesis [12,255]. On the contrary, gliosis induced by β-amyloid(1–42) injection into the frontal cortex (a model of Alzheimer's disease) is potentiated by a CB2 receptor-selective agonist [256].

Collectively, most of the evidence discussed above supports the view that selective CB2 agonists may by useful in treating various neurodegenerative disorders by attenuating glial activation and inflammatory response (cytokine and chemokine secretion, etc.), alongside with decreasing reactive oxygen and nitrogen species generation, and possibly promoting neurogenesis.

Acute or chronic inflammatory response in the brain, spinal cord or at peripheral sites may profoundly affect synaptic transmission leading to pain. In addition to a well-known role of CB1 receptors in pain, recent evidence also implicates CB2 receptors in the antihyperalgesic activity of cannabinoids in models of acute and chronic, neuropathic pain, especially of inflammatory origin [177192], however the detailed discussion of these studies is beyond the scope of this synopsis and is a subject of recent reviews [22,193].

4.6. Psychiatric disorders (schizophrenia, anxiety and depression)

Numerous reports strongly indicate that cannabis use – presumably heavy use – may cause psychotic reactions in healthy individuals [257,258]. Cannabis use in adolescence or early adulthood carries a close to two fold increase in the risk of subsequent development of schizophrenia [194], which most likely may involve chronic dysregulation of the CB1 receptors and/or receptor signaling. It has also been hypothesized that irregularities of the endocannabinoid system may lead to schizophrenia [195], however this assumptions needs additional confirmation. The levels of anandamide in the blood are higher in patients with acute schizophrenia than in healthy volunteers [196], and the clinical remission is associated with decrease of these levels, as well as with decrease of the mRNA encoding the CB2 receptor. These results are also consistent with higher levels of anandamide in the cerebrospinal fluid (CSF) of patients in the initial (prodromal) states of psychosis compared to healthy volunteers [259]. Interestingly, patients with lower levels of anandamide had a higher risk of later development of schizophrenia, indicating that the endocannabinoid system may have a protective role (opposite to the effects of chronic cannabis use). A recent study has investigated the genetic associations between CNR2 gene polymorphisms and schizophrenia and functions of potentially associated single nucleotide polymorphisms (SNPs) in cultured cells and human postmortem brain [15]. The analysis of two populations revealed significant associations between schizophrenia and SNPs. Two alleles were significantly increased among 1920 patients with schizophrenia compared with 1920 control subjects. A lower response to CB2 ligands in cultured CHO cells transfected with one of the alleles, and significantly lower CB2 receptor mRNA and protein levels were found in human cadaver brain with the genotypes of the second allele. In the same study, the effects of the CB2 receptor antagonist AM630 on mouse behavior were also investigated [15]. AM630 exacerbated MK-801- or methamphetamine-induced disturbance of prepulse inhibition (PPI, an animal model of schizophrenia) and hyperactivity in mice. On the basis of these studies the authors concluded that people with low CB2 receptor function are at increased risk for the development of schizophrenia. In contrast, in a rat model of social isolation (another model of schizophrenia) AM630 failed to affect any of the cognitive deficits (object recognition and contextual fear conditioning) studied [16], suggesting that CB2 receptors do not play significant role in these paradigms.

Experimental treatment of depression and anxiety with cannabis, and later with THC, has been reported for over 150 years since Jacques-Joseph Moreau de Tours proposed its use in melancholia [260]. The results published over decades stretch from highly positive to adverse [197,198]. In view of the well known biphasic effects of cannabinoids [261], these observations are not unexpected. Since the discovery of the endocannabinoid system numerous publications tried to address its role in anxiety and depression. Because the CB2 receptor was considered to be absent in the brain, the original assumption was that the CB1 receptors are responsible for mediating all CNS effects of THC and endocannabinoids, which has been covered by outstanding recent overviews [262,263]. A few typical examples of the lessons learnt from pre-clinical and clinical studies in this regard: (a) knockout mice displayed increased anxiety-like behavior compared to wild-type controls under conditions that are stressful to the animals and have increased sensitivity to develop anhedonia in a model of depression [264]; (b) subjects with a life-time diagnosis of major depression had increased CB1 receptor mRNA levels in the dorsolateral prefrontal cortex of [265]; (c) clinical trials of rimonabant, a CB1 antagonist for the treatment of obesity, reported increased dose-dependent anxiety and depression in some patients as adverse events [266].

With the discovery of the presence of CB2 receptor in the brain [51,267] several groups have addressed the possible effects on depression by stimulation of this receptor. Onaivi et al. found that there is a high incidence of Q63R polymorphism in the CB2 gene in Japanese depressed subjects [17]. Garcia-Gutierrez et al. [18] using transgenic mice overexpressing the CB2 receptor (CB2xP mice) found decreased depressive-like behaviors in the tail suspension and a novelty-suppressed feeding tests, compared to wild type mice. The expression of brain-derived neurotrophic factor (BDNF) is downregulated in the hippocampus of wild type mice exposed to unpredictable chronic mild stress. In contrast, no changes in BDNF gene and protein expressions were observed in stressed CB2xP mice. It is well known that BDNF plays an important role in adult neurogenesis and that reduction of hippocampal neurogenesis occurs in patients with mood disorders. Hence, the observations described by Garcia-Gutierrez et al. indicate a possible mechanism of the anti-depressant action of the CB2 receptor system [18]. However, acute administration of the CB2 receptor antagonist AM630 exerted antidepressant-like effects in a forced swimming test in wild type, but not in CB2xP mice. This effect, apparently contradictory to the results described above, was explained on the basis of a possible increase of CB2 receptor levels by an antagonist, a phenomenon previously seen with other receptors [268]. Hu et al. [19] have compared the antidepressant action of the CB2 agonist GW405833 with the action of desipramine, a widely used antidepressant, in a chronic model of neuropathic pain, which causes depression-like behavior in animals. In this study mechanical hypersensitivity (a pain assay), time of immobility and climbing behavior in a swimming assay (depression assays) were used. Rats with chronic neuropathic pain displayed a significant mechanical hypersensitivity and a significant increase in time of immobility. Both desipramine and GW405833 significantly reduced immobility; however only GW-405,833 showed anti-nociceptive properties. Though, contrary to desipramine, GW-405,833 did not change the climbing behavior. Increased expression of the CB2 receptor has also been shown to lead to reduction of anxiogenic-like behavior in mice [20]. The response to stress was also lower. Surprisingly, the action of anxiolytic drugs was impaired in the same study.

Even though the above mentioned studies envision the possibility of modulating schizophrenia and affective disorders by CB2 agonists, it would be extremely important to confirm the exact localization and function of CB2 receptors in the brain, which is still a very controversial issue. It should also be considered that multiple lines of evidence support a view that the depression itself can be a consequence of a chronic inflammatory process and immune system dysfunction, conversely many conventional antidepressants exert anti-inflammatory effects [269]. From this perspective modulation of the chronic inflammation by CB2 receptor ligands may have a reasonable therapeutic rational. The multifaceted nature of human mood disorders should also be kept in mind and the lack of reliable animal models of these diseases. For example, multiple pre-clinical studies based on these animal models also predicted a possible usefulness of CB1 inverse agonists/antagonists as antidepressants [270]. Nevertheless, modulating mood disorders with cannabinergic ligands remains a provocative possibility, which warrants future studies.

4.7. Skin, allergic and autoimmune disorders (allergic dermatitis, asthma bronchiale, rheumatoid arthritis, slceroderma, etc.)

Multiple lines of recent evidence supports the existence of a functional endocannabinoid system in skin which is involved in maintenance of the balanced control of the growth, proliferation, differentiation, apoptosis, and cytokine/mediator/hormone production of various cell types (e.g. keratinocytes, sebocytes, immune cells, etc.) of the skin and appendages (e.g. sebaceous gland, hair follicle) [32]. AEA and/or 2-AG are detectable in rodent skin [177,199] and in human organ-cultured hair follicles [271] and sebocytes [272] alongside with AEA transporter, synthetic and metabolizing enzymes (NAPE-PLD and FAAH) in cultured keratinocytes [273], and in murine epidermal cells/skin [199]. Both cannabinoid receptors are identified on cultured human primary keratinocytes [32,273,274], and CB2 expression is detectable in human sebaceous gland-derived sebocytes [272].

Disturbance of the above mentioned tight control may promote the development of multiple pathological conditions/diseases of the skin, such as acne, seborrhea, allergic dermatitis, itch and pain, psoriasis, hair growth disorders, systemic sclerosis, and cancer, among others (reviewed in [32]). CB1 and CB2 receptors were described in several murine and human skin cell populations (e.g. mast cells, cutaneous nerve fibers, epidermal keratinocytes, and cells of the adnexal tissues [182,199,207,271,272,275,276]. While hair growth appears to be under CB1-mediated endocannabinoid signaling control (CB1 antagonists promote hair growth in mice [277]), CB2 receptors may be involved in control of lipid production and cell death in sebocytes [272].

Although it is generally recognized that the endocannabinoid system has immunosuppressive, thus anti-inflammatory effects in many models of sterile inflammation [10,77], some controversies do exist regarding the skin contact dermatitis. Using well-established preclinical models for acute and chronic contact dermatitis, Oka et al. [201] demonstrated elevated 2-AG levels in the inflamed skin. They also showed that the symptoms of skin inflammation were dramatically attenuated by CB2 (but not CB1) antagonists/inverse agonists [201]. Ueda et al. using a different approach to induce allergic contact dermatitis also reported suppression of the cutaneous inflammatory response by orally administered CB2 antagonists/inverse agonists [200,278], as well as in the CB2 deficient mice [200]. In contrast, Karsak et al. [199] suggested that the endocannabinoid system has a protective role in allergic inflammation of the skin. They demonstrated increased levels of endocannabinoids in skin of mice with contact dermatitis and showed that mice lacking both CB1 and CB2 (or treated with antagonists of these receptors) displayed a markedly exacerbated allergic inflammatory response. Notably, the CB2 agonist HU-308 alone was not sufficient to afford any protection against allergic skin inflammation. The existence of the endocannabinoid-mediated protection was also supported by attenuated allergic response in the skin of FAAH-deficient mice, which have increased levels of the endocannabinoid AEA. Furthermore, the skin inflammation was decreased by locally administered THC [199]. The reasons for the above mentioned conflicting findings are not clear. They may be due to the different approaches utilized to induce the dermatitis. Recently, Zheng et al. [208], using CB1/2 double knockout mice, provided evidence that endocannabinoids may promote the UVB-induced cutaneous inflammatory processes, since these mice showed remarkable resistance to inflicted damage. Collectively, the above mentioned studies support a therapeutic potential in allergic skin inflammation of CB2 inverse agonists/antagonists or perhaps ligands which raise endocannabinoid levels or simultaneously target both CB1 and CB2 (like THC). Notably, THC has been reported to exert various receptor-independent anti-inflammatory and antioxidant effects, which could contribute to its local anti-inflammatory property [279].

Akhmetshina et al. [202] investigated the role of CB2 receptors in bleomycin-induced dermal fibrosis (an animal model of systemic sclerosis/scleroderma (a systemic autoimmune disorder)). They found that CB2 knockout mice or control mice treated with CB2 antagonist AM630 developed increased dermal thickness and leukocyte infiltration in skin. Using bone marrow transplantation they also elegantly demonstrated that the leukocytes expressing CB2 were critically involved in the development of experimental fibrosis [202]. Conversely, the CB2 agonist JWH-133 attenuated dermal fibrosis and inflammation upon treatment implying a therapeutic potential of selective CB2 agonists for the treatment of early inflammatory stages of systemic sclerosis. Utilizing a different mouse model of systemic sclerosis Servettaz et al. reported that treatment with WIN-55,212 or with the selective CB2 agonist JWH-133 prevented the development of skin and lung fibrosis as well as reduced fibroblast proliferation and the development of autoanti-bodies. Consistently, the importance of CB2 in the development of systemic fibrosis and autoimmunity was also confirmed using CB2 knockout mice [203].

CB2 agonists could theoretically exert multiple beneficial effects on rheumatoid arthritis (an autoimmune disorder), and perhaps some other degenerative joint disorders including: (a) immuno-suppression (inhibition of proliferation, apoptosis, suppression of cytokine and chemokine production in immune cells, and induction of T regulatory cells) and consequent attenuation of autoimmune inflammatory response; (b) attenuation of fibrosis in connective tissues (attenuation of fibroblast proliferation); (c) decrease in pain and neurogenic inflammation; and (d) anabolic effects on bone metabolism. As already discussed in previous parts, large number of studies support a possibly therapeutic utility of selective CB2 agonists in chronic inflammatory pain (in fact, many pre-clinical models of inflammatory pain are based on injections of irritants triggering joint or skin inflammation in rodents), as well as in various bone and inflammatory disorders. CB1 and CB2 receptors and FAAH activity are detectable in the synovia of patients with osteoarthritis and rheumatoid arthritis, and the synovial fluid of these patients (but not normal volunteers) contains measurable endocannabinoid (AEA and 2-AG) levels, suggesting that a functional endocannabinoid system exists in the synovium, which may be therapeutically exploited for the treatment of pain and inflammation associated with osteoarthritis and rheumatoid arthritis in humans [204].

A recent study using a murine model of allergen-induced airway inflammation (asthma bronchiale) demonstrated that THC treatment of C57BL/6 wild type mice dramatically reduced airway inflammation as determined by reduced total cell counts in bronchoalveolar lavage fluid [280]. These effects were greatest when mice were treated during both the sensitization and the challenge phases. Besides, systemic immune responses were significantly suppressed in mice which received THC during the sensitization phase. However, no changes in lung inflammation were observed using pharmacological blockade of CB1 and/or CB2 receptors in the same model or using CB1/2 receptor double-knockout mice. Furthermore, neither significant change in the cell patterns in BAL nor in immunoglobulin levels were found as compared to wild type mice. These result indicated that THC exerted CB1/2 receptor-independent anti-inflammatory effects. These results in agreement with a previous study demonstrating that THC administered before sensitization to allergen ovalbumin and then before challenge, significantly attenuated the elevation of IL-2, IL-4, IL-5, and IL-13 steady-state mRNA expression elicited by ovalbumine challenge in the lungs, as well as the elevation of serum and mucus IgE overproduction [281]. Other recent studies demonstrated that the mixed cannabinoid CB1/2 receptor agonist WIN-55,212-2 inhibited antigen-induced plasma extravasation and neurogenic inflammation in guinea pig airways, which could be reversed by CB2, but not CB1 antagonist, implicating a CB2-mediated anti-inflammatory effect [205,206]. Endocannabinoids and synthetic ligands through the activation of CB2 receptors may also play an important role in controlling the mast cell mediator release, and these cells are critical in the initiation of the inflammatory process associated with asthma, as well as with allergic skin and other diseases [282].

Numerous earlier studies have implicated a possible role of the endocannabinoid system in the control of airway smooth muscle relaxation, but this is still a controversial issue, which was previously reviewed in detail [10]. Thus, the effects of cannabinoids on respiratory function are rather complex, but evidence for their possibly usefulness as adjuncts treatment of allergic asthma is emerging.

4.8. Cancer

Cannabinoids have well documented palliative effects in cancer patients such as appetite stimulation, inhibition of nausea and emesis associated with chemo- or radiotherapy, pain relief, mood elevation, and relief from insomnia [10]. Evidence based on: (a) studies evaluating the effects endocannabinoids or cannabinergic ligands in various cancer cell lines or rodent models of explanted tumors; (b) epidemiological studies investigating the relationship of cannabis smoking and various forms of cancer; and (c) association studies in which CB1/2 receptor expressions, endocannabinoids and their metabolizing enzyme expressions and/or activities were determined in various human cancers and correlated with pain, survival, and other determinants of progression, yielded inconsistent, often conflicting results suggesting that cannabinoids may both promote or inhibit cancer growth depending on tumor or cancer cell line and/or experimental condition (reviewed in [10,23,24]). The proposed mechanisms of cancer growth inhibition are multifaceted and may comprise of antiproliferative effect, induction of apoptosis in tumor cells, and attenuation of metastatic formation through inhibition of angiogenesis and tumor cell migration [10,23,24]. However, many of these effects can not clearly be linked to cannabinoid receptor activation. Furthermore, often there is no obvious association between expression of cannabinoid receptors in tumors (or tumor endocannabinoid levels) and the disease progression or patients’ survival [10,23,24,26]. Instead of detailed discussion of these studies, we will provide only a few characteristic examples reflecting the overall situation in the field, and refer readers to several excellent recent overviews on this subject [2326]. Casanova et al. [275] reported that human skin carcinomas (e.g. basal cell carcinoma, squamous cell carcinoma) express both CB1 and CB2, and that local administration of synthetic CB1/2 agonists triggered marked growth inhibition of malignant inoculated skin tumors accompanied by enhanced intra-tumor apoptosis and impaired tumor vascularization (altered blood vessel morphology, decreased expression of pro-angiogenic factors such as VEGF). Cannabinoids were also reported to inhibit the in vivo growth of melanomas that express CB1 and CB2, by decreasing growth, proliferation, angiogenesis and metastasis formation, while increasing apoptosis [207]. In contrast, a recent study of Zheng et al. [208] showed that CBs are involved in the promotion of in vivo skin carcinogenesis. Using CB1/2 double gene deficient mice, they demonstrated that an absence of CB1/2 receptors resulted in a marked decrease in UVB-induced skin carcinogenesis [208].

The levels of CB2 receptor and its endogenous ligand 2-AG are elevated in endometrial carcinoma [210] and CB2 receptors are also expressed on malignancies of the immune system [209]. In immune cancer cells CB2 stimulation triggered apoptosis, suggesting that selective CB2 ligands may serve as novel anticancer agents to selectively target and kill tumors of immune origin [209].

As the above mentioned examples clearly illustrate that the situation regarding the role of the endocannabinoid system in cancer is very complicated and may largely depend on the tumor type, expression of cannabinoid receptors in the tumor, tumor microenvironment, and several other factors. On the other hand, several studies are very encouraging in support of the use of cannabinoids not only as palliative therapy, but also because of their ability to inhibit the growth and metastasis formation of certain types of tumors (e.g. in gliomas, tumors of immune origin, etc.). Furthermore, recent milestone discoveries suggesting a key role of the local inflammation in cancer progression, growth and metastasis formation provide additional reasons for future optimism regarding the possibility of therapeutic utility of the selective modulation of CB2 receptors in cancer.

4.9. Metabolic, reproductive and inflammatory eye disorders

The endogenous cannabinoid system through CB1 receptors plays pivotal role in the regulation of energy homeostasis in multiple organs and at multiple regulatory levels (reviewed in [63,215217]), however the role of CB2 receptors in these processes is still very controversial and not supported by any obvious phenotype of CB2 knockout mice. In endocrine pancreas CB2 receptors were densely present in somatostatin-secreting delta cells, but absent in glucagon-secreting alpha cells and in insulin-secreting beta cells [100]. In contrast, other studies concluded that CB1 and CB2 receptors in beta cells may be present and/or regulate insulin secretion [283,284]. Agudo et al. [138] found that CB2 receptor knockout mice had greater age-dependent increases in food intake and body weight, however, even at 12-month age these obese CB2–/– mice did not develop insulin resistance and showed enhanced insulin-stimulated glucose uptake in skeletal muscle. They also showed that adipose tissue hypertrophy was not associated with inflammation [138] and that treatment of wild-type mice with CB2R antagonist resulted in improved insulin sensitivity. Moreover, when 2-month-old CB2–/– mice were fed a high-fat diet, reduced body weight gain and normal insulin sensitivity were observed. These results indicated that the lack of CB2R-mediated responses protected mice from both age-related and diet-induced insulin resistance, suggesting that these receptors may be a potential therapeutic target in obesity and insulin resistance [138]. In contrast in another study, Deveaux et al. [136] showed in both high fat-fed wide type mice and ob/ob mice (model of obesity), that CB2 receptor expression underwent a marked induction in the stromal vascular fraction of epididymal adipose tissue that correlated with increased fat accumulation and inflammation. Treatment with the CB2 agonist JWH-133 potentiated adipose tissue inflammation in high fat diet-fed wild type mice and the high fat diet-induced insulin resistance increased in response to JWH-133 and was reduced in CB2–/– mice. Similarly, JWH-133 also enhanced the high fat diet-induced hepatic steatosis in WT mice which was blunted in CB2–/– mice. This study suggested that CB2 receptor antagonists may open a new therapeutic approach for the management of obesity-associated metabolic disorders. Nevertheless, further studies are warranted to investigate the role of CB2 receptors and its peculiar cellular targets in context of metabolic disorders.

The endocannabinoid system and CB2 receptors have also been implicated in various dysfunctions of the reproductive system [29,30], and selective CB2 upregulation was reported in women affected by endometrial inflammation [211]. This topic was recently covered by several excellent overviews [29,30].

Xu et al. reported anti-inflammatory property of the CB2 receptor agonist JWH-133 in a rodent model of autoimmune uveoretinitis (uveitis can be often a consequence of various systemic autoimmune diseases in humans), which was explained via inhibition of the activation and function of autoreactive T cells and prevention of leukocyte trafficking into the inflamed tissue [212].

5. Conclusions

Overwhelming evidence has established an important role for endocannabinoid-CB2 receptor signaling in a large number of the major pathologies affecting humans. The broad spectrum of actions that can be attributed to CB2 receptor signaling in inflammatory, autoimmune, cardiovascular, gastrointestinal, liver, kidney, neuro-degenerative, psychiatric and many other diseases have been reviewed here in some detail (Fig. 1 and Table 2). Most likely, the primary cellular targets and executors of the CB2 receptor-mediated effects of endocannabinoids or synthetic agonists are the immune and immune-derived cells (e.g. leukocytes, various populations of T and B lymphocytes, monocytes/macrophages, dendritic cells, mast cells, microglia in the brain, Kupffer cells in the liver, etc.), however the number of other potential cellular targets is also expanding, including now endothelial and smooth muscle cells, fibroblasts of various origin, cardiomyocytes, and certain neuronal elements of the peripheral or central nervous systems (Fig. 2). Interestingly, it appears that in many of the above mentioned pathological conditions the inflammation/tissue injury not only triggers rapid elevation in local endocannabinoid level, which in turn initiates fast signaling processes in immune and perhaps other cell types modulating their critical functions, but may also lead to marked increases in CB2 receptor expressions both in inflammatory, as well as in some parenchymal cells. However, the drastic elevation in CB2 receptor expressions recently reported in various diseased tissues calls for some cautious note until these studies are confirmed using more rigorous positive and negative controls and supported by functional evidence. The latter is extremely important given the known, but often ignored limitations of the recently available CB2 antibodies and knockout mouse models.

In immune or immune derived cells CB2 activation generally mediates immunosuppressive effects comprising inhibition of proliferation, induction of apoptosis, suppression of cytokine and chemokine production and migration of stimulated immune cells, and induction of T regulatory cells, with consequent attenuation of autoimmune inflammatory response. These effects limit the tissue injury in large number of the above mentioned pathological conditions, particularly in those associated with sterile inflammatory response. However, in other disease states these immunosuppressive effects of the CB2 receptor activation may enhance or even inflict tissue damage as discussed in previous parts (e.g. in infections with various live pathogens, certain types of cancers in which the protective role of the immune system is critical to control the cancer growth, etc.). It is also important to keep in mind that even the relatively selective CB2 agonists may activate CB1 receptors in target tissues, particularly at higher doses (often resulting in opposite cellular and functional consequences on the disease progression as it became evident in many pathological conditions recently) and when the relative expression of CB1 over CB2 is high in the diseased tissue. This can also be one explanation for the bell-shaped dose response often seen with recently available CB2 agonists in various disease models. Furthermore, in many disease models the CB2 agonists appear to be most effective if given before the initiation of the insult, and may lose their effect or even promote inflammation when given at later time points. Thorough knowledge of CB2 receptor signaling in key target immune and/or other cell types is still largely enigmatic; hence understanding of the precise course of the disease and the exact sequel of pathological events behind these changes is extremely important in order to devise meaningful therapeutic approaches based on targeted modulation of CB2 receptor signaling.

Collectively, multiple lines of evidence discussed above support the view that lipid endocannabinoid signaling through CB2 receptors represents an aspect of the mammalian protective armamentarium, and its modulation by either selective CB2 receptor agonists or inverse agonists/antagonists (depending on the disease and its stage) holds unique therapeutic potential in huge number of diseases (the main targets of CB2 receptor modulation in inflammation and tissue injury are summarized in Fig. 3). Excitingly, large number of novel synthetic [6469] and natural [285,286] CB2 receptor ligands has also been intensively investigated, giving hope that some of the above discussed preclinical results could also be translated into clinical treatments in the near future to ease human sufferings.

Acknowledgements

This study was supported by the Intramural Research Program of NIH/NIAAA (to P.P.) and by NIDA grant #9789 (to R.M.). The authors are indebted to Dr. George Kunos for providing key resources and support and apologize to colleagues whose important work could not be cited because of the size limitations of this review.

Abbreviations

2-AG
2-arachidonoyl glycerol
AEA
anandamide
ALS
amyotrophic lateral sclerosis
CB1/2 receptors
CB1 or CB2 receptors (also termed CNR1 or 2)
CB2–/– or CB2+/+ mice
cannabinoid receptor 2 knockout or wild type mice
CNS
cental nervous system
DAGL
diacyl glycerol lipase
FAAH
fatty acid amine hydrolase
HIV
human immunodeficiency virus
ICAM-1
inter-cellular adhesion molecule 1 (also termed CD54)
I/R
ischemia/reperfusion
LPS
lipopolysaccharide (endotoxin)
iNOS
inducible nitric oxide synthase
MAGL
monoacyl glycerol lipase
MAPK
mitogen-activated protein kinase
MCP-1
monocyte chemoattractant protein (CCL2)
MIP-1a2
macrophage inflammatory protein-1alpha/2 (CCL3 or CXCL2, respectively)
MS
multiple sclerosis
MPTP
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a neurotoxin that causes permanent symptoms of Parkinson's disease by destroying dopaminergic neurons
NK cells
natural killer cells
NOX4, NOX2, and NOX1
isoforms of reactive oxygen species generating NADPH oxidase enzyme
PMNs cells
polymorphonuclear leukocytes/granulocytes
THC
Δ9-tetrahydrocannabinol
TNF-α
tumor necrosis factor-alpha
NF-κβ
nuclear factor kappaB
RANKL
receptor activator of nuclear factor kappa-B ligand
RhoA
a small GTPase protein
ROS/RNS
reactive oxygen or nitrogen species
VCAM-1
vascular adhesion molecule 1 (also termed CD106)

References

1. Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Batkai S, Kunos G. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension. 2008;52:601–7. [PMC free article] [PubMed]
2. Pacher P, Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol. 2009;31:63–77. [PMC free article] [PubMed]
3. Izzo AA, Camilleri M. Cannabinoids in intestinal inflammation and cancer. Pharmacol Res. 2009;60:117–25. [PubMed]
4. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010;126:21–38. [PubMed]
5. Mallat A, Lotersztajn S. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol. 2008;294:G9–G12. [PubMed]
6. Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, Manin S, et al. CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol. 2008;153:286–9. [PubMed]
7. Pacher P, Gao B. Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. Am J Physiol Gastrointest Liver Physiol. 2008;294:G850–4. [PMC free article] [PubMed]
8. Mukhopadhyay P, Rajesh M, Pan H, Patel V, Mukhopadhyay B, Batkai S, et al. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med. 2010;48:457–67. [PMC free article] [PubMed]
9. Mukhopadhyay P, Pan H, Rajesh M, Batkai S, Patel V, Harvey-White J, et al. CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br J Pharmacol. 2010;160:657–68. [PubMed]
10. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58:389–462. [PMC free article] [PubMed]
11. Centonze D, Finazzi-Agro A, Bernardi G, Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci. 2007;28:180–7. [PubMed]
12. Fernandez-Ruiz J, Romero J, Velasco G, Tolon RM, Ramos JA, Guzman M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci. 2007;28:39–45. [PubMed]
13. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F. CB2 receptors in the brain: role in central immune function. Br J Pharmacol. 2008;153:240–51. [PubMed]
14. Fernandez-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol. 2009;156:1029–40. [PubMed]
15. Ishiguro H, Horiuchi Y, Ishikawa M, Koga M, Imai K, Suzuki Y, et al. Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry. 2010;67:974–82. [PubMed]
16. Khan A, Kendall DA, Fone KCF. The effects of the cannabinoid CB2 receptor antagonist, AM630, on isolation rearing – induced behavioural deficits in rats. Schizophr Res. 2010;117:391–2.
17. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann NY Acad Sci. 2008;1139:434–49. [PMC free article] [PubMed]
18. Garcia-Gutierrez MS, Perez-Ortiz JM, Gutierrez-Adan A, Manzanares J. Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br J Pharmacol. 2010;160:1773–84. [PubMed]
19. Hu B, Doods H, Treede RD, Ceci A. Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. Pain. 2009;143:206–12. [PubMed]
20. Garcia-Gutierrez MS, Manzanares J. Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice. J Psychopharmacol. 2011;25(1):111–20. [PubMed]
21. Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev. 2009;60:255–66. [PubMed]
22. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008;153:319–34. [PubMed]
23. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003;3:745–55. [PubMed]
24. Pisanti S, Bifulco M. Endocannabinoid system modulation in cancer biology and therapy. Pharmacol Res. 2009;60:107–16. [PubMed]
25. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia. 2010;58:1017–30. [PMC free article] [PubMed]
26. Fowler CJ, Gustafsson SB, Chung SC, Persson E, Jacobsson SO, Bergh A. Targeting the endocannabinoid system for the treatment of cancer – a practical view. Curr Top Med Chem. 2010;10:814–27. [PubMed]
27. Bab I, Zimmer A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol. 2008;153:182–8. [PubMed]
28. Bab I, Zimmer A, Melamed E. Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Ann Med. 2009;41:560–7. [PubMed]
29. Maccarrone M. CB2 receptors in reproduction. Br J Pharmacol. 2008;153:189–98. [PubMed]
30. Maccarrone M. Endocannabinoids: friends and foes of reproduction. Prog Lipid Res. 2009;48:344–54. [PubMed]
31. Grimaldi P, Orlando P, Di Siena S, Lolicato F, Petrosino S, Bisogno T, et al. The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. Proc Natl Acad Sci USA. 2009;106:11131–6. [PubMed]
32. Biro T, Toth BI, Hasko G, Paus R, Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. 2009;30:411–20. [PMC free article] [PubMed]
33. Mechoulam R, Hanus L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids. 2000;108:1–13. [PubMed]
34. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646–7.
35. Gill EW, Lawrence DK. The physiological mode of action of tetrahydrocannabinol on cell membranes. Pharmacol Marihuana. 1976;1:147–55.
36. Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Jarbe TU, Hiltunen AJ, et al. Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia. 1988;44:762–4. [PubMed]
37. Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34:605–13. [PubMed]
38. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561–4. [PubMed]
39. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–5. [PubMed]
40. Godlewski G, Offertaler L, Wagner JA, Kunos G. Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat. 2009;89:105–11. [PMC free article] [PubMed]
41. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3:771–84. [PubMed]
42. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. 2010;62:588–631. [PubMed]
43. Brown AJ, Daniels DA, Kassim M, Brown S, Haslam CP, Terrell VR, et al. Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity GlyT1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther. in press. doi:10.1124/jpet.110.172650. [PubMed]
44. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev. 1999;51:159–212. [PubMed]
45. Di Marzo V, De Petrocellis L. Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem. 2010;17:1430–49. [PubMed]
46. Grueter BA, Brasnjo G, Malenka RC. Postsynaptic TRPV1 triggers cell type-specific long-term depression in the nucleus accumbens. Nat Neurosci. 2010;13:1519–25. [PMC free article] [PubMed]
47. Chavez AE, Chiu CQ, Castillo PE. TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat Neurosci. 2010;13:1511–8. [PMC free article] [PubMed]
48. Di Marzo V. Anandamide serves two masters in the brain. Nat Neurosci. 2010;13:1446–8. [PubMed]
49. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161–202. [PubMed]
50. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol. 2010;160:467–79. [PubMed]
51. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310:329–32. [PubMed]
52. Borner C, Smida M, Hollt V, Schraven B, Kraus J. Cannabinoid receptor type 1-and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J Biol Chem. 2009;284:35450–60. [PubMed]
53. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–9. [PubMed]
54. Devane WA, Breuer A, Sheskin T, Jarbe TU, Eisen MS, Mechoulam R. A novel probe for the cannabinoid receptor. J Med Chem. 1992;35:2065–9. [PubMed]
55. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83–90. [PubMed]
56. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215:89–97. [PubMed]
57. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4:873–84. [PubMed]
58. Hanus LO, Mechoulam R. Novel natural and synthetic ligands of the endocannabinoid system. Curr Med Chem. 2010;17:1341–59. [PubMed]
59. Wang J, Ueda N. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat. 2009;89:112–9. [PubMed]
60. Cravatt BF, Lichtman AH. The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem Phys Lipids. 2002;121:135–48. [PubMed]
61. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem. 2005;74:411–32. [PubMed]
62. Fezza F, De Simone C, Amadio D, Maccarrone M. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcell Biochem. 2008;49:101–32. [PubMed]
63. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov. 2008;7:438–55. [PubMed]
64. Brogi S, Corelli F, Di Marzo V, Ligresti A, Mugnaini C, Pasquini S, et al. Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2. Eur J Med Chem. 2011;46(2):547–55. [PubMed]
65. Gilbert EJ, Zhou G, Wong MK, Tong L, Shankar BB, Huang C, et al. Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors. Bioorg Med Chem Lett. 2010;20:608–11. [PubMed]
66. Tong L, Shankar BB, Chen L, Rizvi R, Kelly J, Gilbert E, et al. Expansion of SAR studies on triaryl bis sulfone cannabinoid CB2 receptor ligands. Bioorg Med Chem Lett. 2010;20:6785–9. [PubMed]
67. Thakur GA, Tichkule R, Bajaj S, Makriyannis A. Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat. 2009;19:1647–73. [PubMed]
68. Lange JH, van der Neut MA, Borst AJ, Yildirim M, van Stuivenberg HH, van Vliet BJ, et al. Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern. Bioorg Med Chem Lett. 2010;20:2770–5. [PubMed]
69. Lunn CA. Updating the chemistry and biology of cannabinoid CB2 receptor-specific inverse agonists. Curr Top Med Chem. 2010;10:768–78. [PubMed]
70. Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol. 2005:1–51. [PubMed]
71. Huffman JW. CB2 receptor ligands. Mini Rev Med Chem. 2005;5:641–9. [PubMed]
72. Wiley JL, Beletskaya ID, Ng EW, Dai Z, Crocker PJ, Mahadevan A, et al. Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. J Pharmacol Exp Ther. 2002;301:679–89. [PubMed]
73. Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, Tuma RF. Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab. 2007;27:1387–96. [PMC free article] [PubMed]
74. Murineddu G, Lazzari P, Ruiu S, Sanna A, Loriga G, Manca I, et al. Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2′,4′-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. J Med Chem. 2006;49:7502–12. [PubMed]
75. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology. 2005;48:658–72. [PubMed]
76. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, et al. The cannabinoid system and immune modulation. J Leukoc Biol. 2003;74:486–96. [PubMed]
77. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5:400–11. [PubMed]
78. Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol. 2007;18:129–40. [PubMed]
79. Cabral GA, Staab A. Effects on the immune system. Handb Exp Pharmacol. 2005:385–423. [PubMed]
80. Cencioni MT, Chiurchiu V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One. 2010;5:e8688. [PMC free article] [PubMed]
81. Miller AM, Stella N. CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol. 2008;153:299–308. [PubMed]
82. Buckley NE. The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol. 2008;153:309–18. [PubMed]
83. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315–424. [PMC free article] [PubMed]
84. Jiang S, Alberich-Jorda M, Zagozdzon R, Parmar K, Fu Y, Mauch P, et al. Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization. Blood. 2011;117:827–38. [PubMed]
85. Onaivi ES. Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology. 2006;54:231–46. [PubMed]
86. Beltramo M. Cannabinoid type 2 receptor as a target for chronic – pain. Mini Rev Med Chem. 2009;9:11–25. [PubMed]
87. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008;153:263–70. [PubMed]
88. Marquez L, Suarez J, Iglesias M, Bermudez-Silva FJ, Rodriguez de Fonseca F, Andreu M, et al. Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One. 2009;4:e6893. [PMC free article] [PubMed]
89. Duncan M, Mouihate A, Mackie K, Keenan CM, Buckley NE, Davison JS, et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol. 2008;295:G78–87. [PubMed]
90. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13:35–7. [PubMed]
91. Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A. Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol. 2008;20(Suppl. 1):69–74. [PubMed]
92. Mukhopadhyay P, Batkai S, Rajesh M, Czifra N, Harvey-White J, Hasko G, et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol. 2007;50:528–36. [PMC free article] [PubMed]
93. Mukhopadhyay P, Rajesh M, Batkai S, Patel V, Kashiwaya Y, Liaudet L, et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res. 2010;85:773–84. [PMC free article] [PubMed]
94. Bouchard JF, Lepicier P, Lamontagne D. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci. 2003;72:1859–70. [PubMed]
95. Rajesh M, Mukhopadhyay P, Hasko G, Huffman JW, Mackie K, Pacher P. CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol. 2008;153:347–57. [PubMed]
96. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. 2005;128:742–55. [PubMed]
97. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 2008;16:553–65. [PubMed]
98. Michalski CW, Laukert T, Sauliunaite D, Pacher P, Bergmann F, Agarwal N, et al. Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology. 2007;132:1968–78. [PMC free article] [PubMed]
99. Michalski CW, Maier M, Erkan M, Sauliunaite D, Bergmann F, Pacher P, et al. Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS One. 2008;3:e1701. [PMC free article] [PubMed]
100. Bermudez-Silva FJ, Suarez J, Baixeras E, Cobo N, Bautista D, Cuesta-Munoz AL, et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia. 2008;51:476–87. [PubMed]
101. Petrella C, Agostini S, Alema GS, Casolini P, Carpino F, Giuli C, et al. Cannabinoid agonist WIN55, 212 in vitro inhibits interleukin-6 (IL-6) and monocyte chemo-attractant protein-1 (MCP-1) release by rat pancreatic acini and in vivo induces dual effects on the course of acute pancreatitis. Neurogastroenterol Motil. 2010;11:1248–56. [PubMed]
102. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman JW, et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol. 2007;293:H2210–8. [PMC free article] [PubMed]
103. Rajesh M, Pan H, Mukhopadhyay P, Batkai S, Osei-Hyiaman D, Hasko G, et al. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol. 2007;82:1382–9. [PMC free article] [PubMed]
104. Bari M, Battista N, Pirazzi V, Maccarrone M. The manifold actions of endocannabinoids on female and male reproductive events. Front Biosci. 2011;16:498–516. [PubMed]
105. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA. 2006;103:696–701. [PubMed]
106. Di Filippo C, Rossi F, Rossi S, D'Amico M. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia–reperfusion injury: involvement of cytokine/chemokines and PMN. J Leukoc Biol. 2004;75:453–9. [PubMed]
107. Pacher P, Hasko G. Endocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioning. Br J Pharmacol. 2008;153:252–62. [PubMed]
108. Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, Bertolotto M, et al. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol. 2009;46:612–20. [PubMed]
109. Defer N, Wan J, Souktani R, Escoubet B, Perier M, Caramelle P, et al. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J. 2009;23:2120–30. [PubMed]
110. Lamontagne D, Lepicier P, Lagneux C, Bouchard JF. The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia. Arch Mal Coeur Vaiss. 2006;99:242–6. [PubMed]
111. Montecucco F, Matias I, Lenglet S, Petrosino S, Burger F, Pelli G, et al. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis. 2009;205:433–41. [PubMed]
112. Mach F, Steffens S. The role of the endocannabinoid system in atherosclerosis. J Neuroendocrinol. 2008;20(Suppl. 1):53–7. [PubMed]
113. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 2005;434:782–6. [PubMed]
114. Zhao Y, Yuan Z, Liu Y, Xue J, Tian Y, Liu W, et al. Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. J Cardiovasc Pharmacol. 2010;55:292–8. [PubMed]
115. Montecucco F, Burger F, Mach F, Steffens S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol. 2008;294:H1145–55. [PubMed]
116. Pacher P, Ungvari Z. Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases. Am J Physiol Heart Circ Physiol. 2008;294:H1133–4. [PMC free article] [PubMed]
117. Sugamura K, Sugiyama S, Nozaki T, Matsuzawa Y, Izumiya Y, Miyata K, et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation. 2009;119:28–36. [PubMed]
118. Naccarato M, Pizzuti D, Petrosino S, Simonetto M, Ferigo L, Grandi FC, et al. Possible Anandamide and Palmitoylethanolamide involvement in human stroke. Lipids Health Dis. 2010;9:47. [PMC free article] [PubMed]
119. Hillard CJ. Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr Pharm Des. 2008;14:2347–61. [PMC free article] [PubMed]
120. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience. 2004;129:743–50. [PubMed]
121. Zhang M, Adler MW, Abood ME, Ganea D, Jallo J, Tuma RF. CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvasc Res. 2009;78:86–94. [PMC free article] [PubMed]
122. Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, Tuma RF. Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience. 2008;152:753–60. [PMC free article] [PubMed]
123. Baty DE, Zhang M, Li H, Erb CJ, Adler MW, Ganea D, et al. Cannabinoid CB2 receptor activation attenuates motor and autonomic function deficits in a mouse model of spinal cord injury. Clin Neurosurg. 2008;55:172–7. [PubMed]
124. Murikinati S, Juttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z, et al. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J. 2010;24:788–98. [PubMed]
125. Weis F, Beiras-Fernandez A, Sodian R, Kaczmarek I, Reichart B, Beiras A, et al. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. J Mol Cell Cardiol. 2010;48:1187–93. [PubMed]
126. Kohro S, Imaizumi H, Yamakage M, Masuda Y, Namiki A, Asai Y. Reductions in levels of bacterial superantigens/cannabinoids by plasma exchange in a patient with severe toxic shock syndrome. Anaesth Intensive Care. 2004;32:588–91. [PubMed]
127. Kohro S, Imaizumi H, Yamakage M, Masuda Y, Namiki A, Asai Y, et al. Anandamide absorption by direct hemoperfusion with polymixin B-immobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis. J Anesth. 2006;20:11–6. [PubMed]
128. Csoka B, Nemeth ZH, Mukhopadhyay P, Spolarics Z, Rajesh M, Federici S, et al. CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. PLoS One. 2009;4:e6409. [PMC free article] [PubMed]
129. Tschop J, Kasten KR, Nogueiras R, Goetzman HS, Cave CM, England LG, et al. The cannabinoid receptor 2 is critical for the host response to sepsis. J Immunol. 2009;183:499–505. [PMC free article] [PubMed]
130. Kurabayashi M, Takeyoshi I, Yoshinari D, Matsumoto K, Maruyama I, Morishita Y. 2-Arachidonoylglycerol increases in ischemia-reperfusion injury of the rat liver. J Invest Surg. 2005;18:25–31. [PubMed]
131. Batkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, Mukhopadhyay P, et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J. 2007;21:1788–800. [PMC free article] [PubMed]
132. Ishii Y, Sakamoto T, Ito R, Yanaga K. F2-isoprostanes and 2-arachidonylglycerol as biomarkers of lipid peroxidation in pigs with hepatic ischemia/reperfusion injury. J Surg Res. 2010;161:139–45. [PubMed]
133. Hegde VL, Hegde S, Cravatt BF, Hofseth LJ, Nagarkatti M, Nagarkatti PS. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol Pharmacol. 2008;74:20–33. [PMC free article] [PubMed]
134. Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P. Endocannabinoids and immune regulation. Pharmacol Res. 2009;60:85–92. [PMC free article] [PubMed]
135. Mendez-Sanchez N, Zamora-Valdes D, Pichardo-Bahena R, Barredo-Prieto B, Ponciano-Rodriguez G, Bermejo-Martinez L, et al. Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver Int. 2007;27:215–9. [PubMed]
136. Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S, et al. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One. 2009;4:e5844. [PMC free article] [PubMed]
137. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115:1298–305. [PMC free article] [PubMed]
138. Agudo J, Martin M, Roca C, Molas M, Bura AS, Zimmer A, et al. Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia. 2010;53:2629–40. [PubMed]
139. Batkai S, Mukhopadhyay P, Harvey-White J, Kechrid R, Pacher P, Kunos G. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol. 2007;293:H1689–95. [PMC free article] [PubMed]
140. Siegmund SV, Schwabe RF. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2008;294:G357–62. [PubMed]
141. Munoz-Luque J, Ros J, Fernandez-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther. 2008;324:475–83. [PMC free article] [PubMed]
142. Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med. 2001;7:827–32. [PubMed]
143. Moezi L, Gaskari SA, Lee SS. Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2008;295:G649–53. [PubMed]
144. Batkai S, Pacher P. Endocannabinoids and cardiac contractile function: pathophysiological implications. Pharmacol Res. 2009;60:99–106. [PMC free article] [PubMed]
145. Teixeira-Clerc F, Belot MP, Manin S, Deveaux V, Cadoudal T, Chobert MN, et al. Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology. 2010;52(3):1046–59. [PMC free article] [PubMed]
146. Avraham Y, Israeli E, Gabbay E, Okun A, Zolotarev O, Silberman I, et al. Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. Neurobiol Dis. 2006;21:237–45. [PubMed]
147. Dagon Y, Avraham Y, Ilan Y, Mechoulam R, Berry EM. Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase. FASEB J. 2007;21:2431–41. [PubMed]
148. Magen I, Avraham Y, Berry E, Mechoulam R. Endocannabinoids in liver disease and hepatic encephalopathy. Curr Pharm Des. 2008;14:2362–9. [PubMed]
149. Borrelli F, Izzo AA. Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. Best Pract Res Clin Endocrinol Metab. 2009;23:33–49. [PubMed]
150. Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology. 2005;129:437–53. [PubMed]
151. Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol. 2006;291:G364–71. [PubMed]
152. Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis. 2009;15:1678–85. [PubMed]
153. Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yuce B, Sibaev A, et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med. 2008;86:925–36. [PubMed]
154. Karsak M, Cohen-Solal M, Freudenberg J, Ostertag A, Morieux C, Kornak U, et al. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet. 2005;14:3389–96. [PubMed]
155. Idris AI, van ‘t Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med. 2005;11:774–9. [PMC free article] [PubMed]
156. Smoum R, Bar A, Tan B, Milman G, Attar-Namdar M, Ofek O, et al. Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci USA. 2010;107:17710–5. [PubMed]
157. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci. 2003;23:11136–41. [PubMed]
158. Benito C, Romero JP, Tolon RM, Clemente D, Docagne F, Hillard CJ, et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci. 2007;27:2396–402. [PubMed]
159. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005;25:1904–13. [PubMed]
160. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem. 2005;95:437–45. [PubMed]
161. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med. 2007;13:492–7. [PubMed]
162. Kim K, Moore DH, Makriyannis A, Abood ME. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol. 2006;542:100–5. [PubMed]
163. Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007;101:87–98. [PMC free article] [PubMed]
164. Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E, et al. WIN55, 212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci. 2009;29:2177–86. [PMC free article] [PubMed]
165. Benito C, Tolon RM, Pazos MR, Nunez E, Castillo AI, Romero J. Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol. 2008;153:277–85. [PubMed]
166. Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain. 2009;132:3152–64. [PubMed]
167. Palazuelos J, Davoust N, Julien B, Hatterer E, Aguado T, Mechoulam R, et al. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem. 2008;283:13320–9. [PubMed]
168. Sagredo O, Gonzalez S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia. 2009;57:1154–67. [PMC free article] [PubMed]
169. Tolon RM, Nunez E, Pazos MR, Benito C, Castillo AI, Martinez-Orgado JA, et al. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res. 2009;1283:148–54. [PubMed]
170. De March Z, Zuccato C, Giampa C, Patassini S, Bari M, Gasperi V, et al. Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions. Neuroscience. 2008;152:734–40. [PubMed]
171. Mestre L, Docagne F, Correa F, Loria F, Hernangomez M, Borrell J, et al. A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol Cell Neurosci. 2009;40:258–66. [PubMed]
172. Loria F, Petrosino S, Hernangomez M, Mestre L, Spagnolo A, Correa F, et al. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol Dis. 2010;37:166–76. [PubMed]
173. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 2005;7:E625–54. [PMC free article] [PubMed]
174. Bisogno T, Di Marzo V. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets. 2010;9(5):564–73. [PubMed]
175. Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A. Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Exp Neurol. 2010;224:37–47. [PubMed]
176. Gorantla S, Makarov E, Roy D, Finke-Dwyer J, Murrin LC, Gendelman HE, et al. Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS. J Neuroimmune Pharmacol. 2010;5:456–68. [PMC free article] [PubMed]
177. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 1998;394:277–81. [PubMed]
178. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA. 1999;96:14228–33. [PubMed]
179. Malan Jr TP, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain. 2001;93:239–45. [PubMed]
180. Clayton N, Marshall FH, Bountra C, O'shaughnessy CT. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain. 2002;96:253–60. [PubMed]
181. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA. 2003;100:10529–33. [PubMed]
182. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA. 2005;102:3093–8. [PubMed]
183. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, et al. CB2 cannabinoid receptor mediation of antinociception. Pain. 2006;122:36–42. [PubMed]
184. Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 2003;119:747–57. [PubMed]
185. Nackley AG. Suplita 2nd RL, Hohmann AG. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 2003;117:659–70. [PubMed]
186. Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG. Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol. 2004;92:3562–74. [PubMed]
187. Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, et al. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology. 2003;99:955–60. [PubMed]
188. Elmes SJ, Jhaveri MD, Smart D, Kendall DA, Chapman V. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci. 2004;20:2311–20. [PubMed]
189. Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther. 2004;308:446–53. [PubMed]
190. Scott DA, Wright CE, Angus JA. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain. 2004;109:124–31. [PubMed]
191. Whiteside GT, Lee GP, Valenzano KJ. The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem. 2007;14:917–36. [PubMed]
192. Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther. 2008;327:584–91. [PMC free article] [PubMed]
193. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6:713–37. [PMC free article] [PubMed]
194. Muller-Vahl KR, Emrich HM. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother. 2008;8:1037–48. [PubMed]
195. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987;2:1483–6. [PubMed]
196. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2003;2:5. [PMC free article] [PubMed]
197. Grinspoon L, Bakalar JB. Marihuana as medicine. A plea for reconsideration. JAMA. 1995;273:1875–6. [PubMed]
198. Grinspoon L, Bakalar JB, Zimmer L, Morgan JP. Marijuana addiction. Science. 1997;277:749. author reply 50–2. [PubMed]
199. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science. 2007;316:1494–7. [PubMed]
200. Ueda Y, Miyagawa N, Wakitani K. Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. Life Sci. 2007;80:414–9. [PubMed]
201. Oka S, Wakui J, Ikeda S, Yanagimoto S, Kishimoto S, Gokoh M, et al. Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice. J Immunol. 2006;177:8796–805. [PubMed]
202. Akhmetshina A, Dees C, Busch N, Beer J, Sarter K, Zwerina J, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum. 2009;60:1129–36. [PubMed]
203. Servettaz A, Kavian N, Nicco C, Deveaux V, Chereau C, Wang A, et al. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am J Pathol. 2010;177:187–96. [PubMed]
204. Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2008;10:R43. [PMC free article] [PubMed]
205. Yoshihara S, Morimoto H, Ohori M, Yamada Y, Abe T, Arisaka O. The cannabinoid receptor agonist WIN 55212-2 inhibits neurogenic inflammations in airway tissues. J Pharmacol Sci. 2005;98:77–82. [PubMed]
206. Fukuda H, Abe T, Yoshihara S. The cannabinoid receptor agonist WIN 55, 212-2 inhibits antigen-induced plasma extravasation in guinea pig airways. Int Arch Allergy Immunol. 2010;152:295–300. [PubMed]
207. Blazquez C, Carracedo A, Barrado L, Real PJ, Fernandez-Luna JL, Velasco G, et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 2006;20:2633–5. [PubMed]
208. Zheng D, Bode AM, Zhao Q, Cho YY, Zhu F, Ma WY, et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res. 2008;68:3992–8. [PMC free article] [PubMed]
209. McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. 2002;100:627–34. [PubMed]
210. Guida M, Ligresti A, De Filippis D, D'Amico A, Petrosino S, Cipriano M, et al. The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma. Endocrinology. 2010;151:921–8. [PubMed]
211. Iuvone T, De Filippis D, Di Spiezio Sardo A, D'Amico A, Simonetti S, Sparice S, et al. Selective CB2 up-regulation in women affected by endometrial inflammation. J Cell Mol Med. 2008;12:661–70. [PMC free article] [PubMed]
212. Xu H, Cheng CL, Chen M, Manivannan A, Cabay L, Pertwee RG, et al. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol. 2007;82:532–41. [PubMed]
213. Pacher P, Batkai S, Kunos G. Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol. 2005:599–625. [PMC free article] [PubMed]
214. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation. 2004;110:1996–2002. [PMC free article] [PubMed]
215. Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, Batkai S. Endocannabinoids and the control of energy homeostasis. J Biol Chem. 2008;283:33021–5. [PubMed]
216. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia. 2008;51:1356–67. [PubMed]
217. Kunos G, Osei-Hyiaman D, Batkai S, Sharkey KA, Makriyannis A. Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci. 2009;30:1–7. [PMC free article] [PubMed]
218. Mukhopadhyay P, Horvath B, Rajesh M, Matsumoto S, Saito K, Batkai S, et al. Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic Biol Med. 2011;50(1):179–95. [PMC free article] [PubMed]
219. Dol-Gleizes F, Paumelle R, Visentin V, Mares AM, Desitter P, Hennuyer N, et al. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2009;29:12–8. [PubMed]
220. Pacher P. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? Arterioscler Thromb Vasc Biol. 2009;29:7–9. [PMC free article] [PubMed]
221. Mach F, Montecucco F, Steffens S. Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol. 2008;153:290–8. [PubMed]
222. Lepicier P, Bibeau-Poirier A, Lagneux C, Servant MJ, Lamontagne D. Signaling pathways involved in the cardioprotective effects of cannabinoids. J Pharmacol Sci. 2006;102:155–66. [PubMed]
223. Hiley CR. Endocannabinoids and the heart. J Cardiovasc Pharmacol. 2009;53:267–76. [PMC free article] [PubMed]
224. Han KH, Lim S, Ryu J, Lee CW, Kim Y, Kang JH, et al. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res. 2009;84:378–86. [PubMed]
225. Freeman-Anderson NE, Pickle TG, Netherland CD, Bales A, Buckley NE, Thewke DP. Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis. J Lipid Res. 2008;49:2338–46. [PubMed]
226. Netherland CD, Pickle TG, Bales A, Thewke DP. Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis. 2010;213:102–8. [PMC free article] [PubMed]
227. Reinhard W, Stark K, Neureuther K, Sedlacek K, Fischer M, Baessler A, et al. Common polymorphisms in the cannabinoid CB2 receptor gene (CNR2) are not associated with myocardial infarction and cardiovascular risk factors. Int J Mol Med. 2008;22:165–74. [PubMed]
228. Avraham Y, Zolotarev O, Grigoriadis NC, Poutahidis T, Magen I, Vorobiav L, et al. Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice. Am J Gastroenterol. 2008;103:3047–56. [PubMed]
229. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med. 2006;12:671–6. [PubMed]
230. Domenicali M, Caraceni P, Giannone F, Pertosa AM, Principe A, Zambruni A, et al. Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. Gastroenterology. 2009;137:341–9. [PubMed]
231. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58:87–114. [PMC free article] [PubMed]
232. Hall D, Poussin C, Velagapudi VR, Empsen C, Joffraud M, Beckmann J, et al. Peroxisomal and microsomal lipid pathways associated with resistance to hepatic steatosis and reduced pro-inflammatory state. J Biol Chem. 2010;285(40):31011–23. [PubMed]
233. Siegmund SV, Qian T, de Minicis S, Harvey-White J, Kunos G, Vinod KY, et al. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J. 2007;21:2798–806. [PubMed]
234. Pandey R, Hegde VL, Singh NP, Hofseth L, Singh U, Ray S, et al. Use of cannabinoids as a novel therapeutic modality against autoimmune hepatitis. Vitam Horm. 2009;81:487–504. [PubMed]
235. Kunos G, Gao B. Endocannabinoids, CB1 receptors, and liver disease: hitting more than one bird with the same stone. Gastroenterology. 2008;134:622–5. [PubMed]
236. Kunos G, Osei-Hyiaman D, Batkai S, Gao B. Cannabinoids hurt, heal in cirrhosis. Nat Med. 2006;12:608–10. [PubMed]
237. Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G. Endocannabinoids in liver disease. Hepatology. 2011;53(1):346–55. [PMC free article] [PubMed]
238. Patel KD, Davison JS, Pittman QJ, Sharkey KA. Cannabinoid CB(2) receptors in health and disease. Curr Med Chem. 2010;17:1393–410. [PubMed]
239. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest. 1997;100:1538–46. [PMC free article] [PubMed]
240. Janiak P, Poirier B, Bidouard JP, Cadrouvele C, Pierre F, Gouraud L, et al. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int. 2007;72:1345–57. [PubMed]
241. Karsenty G. The complexities of skeletal biology. Nature. 2003;423:316–8. [PubMed]
242. Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, van Wijnen AJ, et al. Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr. 2004;14:1–41. [PubMed]
243. Tam J, Trembovler V, Di Marzo V, Petrosino S, Leo G, Alexandrovich A, et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J. 2008;22:285–94. [PubMed]
244. Rossi F, Siniscalco D, Luongo L, De Petrocellis L, Bellini G, Petrosino S, et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone. 2009;44:476–84. [PubMed]
245. Rossi F, Bellini G, Luongo L, Torella M, Mancusi S, De Petrocellis L, et al. The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy. Bone. in press. doi:10.1016/j.bone.2011.01.001.
246. Yamada Y, Ando F, Shimokata H. Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. Int J Mol Med. 2007;19:791–801. [PubMed]
247. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 2001;413:527–31. [PubMed]
248. Pope C, Mechoulam R, Parsons L. Endocannabinoid signaling in neurotoxicity and neuroprotection. Neurotoxicology. 2010;31(5):562–71. [PMC free article] [PubMed]
249. Sarne Y, Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord. 2005;4:677–84. [PubMed]
250. Nunez E, Benito C, Pazos MR, Barbachano A, Fajardo O, Gonzalez S, et al. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse. 2004;53:208–13. [PubMed]
251. Benito C, Nunez E, Pazos MR, Tolon RM, Romero J. The endocannabinoid system and Alzheimer's disease. Mol Neurobiol. 2007;36:75–81. [PubMed]
252. Nunez E, Benito C, Tolon RM, Hillard CJ, Griffin WS, Romero J. Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience. 2008;151:104–10. [PubMed]
253. Ashton JC, Rahman RM, Nair SM, Sutherland BA, Glass M, Appleton I. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett. 2007;412:114–7. [PubMed]
254. Viscomi MT, Oddi S, Latini L, Pasquariello N, Florenzano F, Bernardi G, et al. Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci. 2009;29:4564–70. [PubMed]
255. Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzman M, Galve-Roperh I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 2006;20:2405–7. [PubMed]
256. Esposito G, Iuvone T, Savani C, Scuderi C, De Filippis D, Papa M, et al. Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence. J Pharmacol Exp Ther. 2007;322:1144–52. [PubMed]
257. Sewell RA, Ranganathan M, D'souza DC. Cannabinoids and psychosis. Int Rev Psychiatry. 2009;21:152–62. [PubMed]
258. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, et al. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med. 2009;39:1607–16. [PubMed]
259. Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, et al. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry. 2009;194:371–2. [PubMed]
260. Moreau de Tours JJ. Lypermanie avec stupeur; tendence a la demence–traitment par l'extract de cannabis sativa. Lancette Gazette Hopital. 1857;30:391.
261. Sulcova E, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav. 1998;59:347–52. [PubMed]
262. Mangieri RA, Piomelli D. Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacol Res. 2007;56:360–6. [PMC free article] [PubMed]
263. Hill MN, Gorzalka BB. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol. 2005;16:333–52. [PubMed]
264. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 2002;159:379–87. [PubMed]
265. Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB, et al. Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry. 2004;9:184–90. [PubMed]
266. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121–34. [PubMed]
267. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann NY Acad Sci. 2006;1074:514–36. [PubMed]
268. Patel M, Gomes B, Patel C, Yoburn BC. Antagonist-induced micro-opioid receptor up-regulation decreases G-protein receptor kinase-2 and dynamin-2 abundance in mouse spinal cord. Eur J Pharmacol. 2002;446:37–42. [PubMed]
269. Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann NY Acad Sci. 2009;1179:86–105. [PMC free article] [PubMed]
270. Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci. 2005;26:609–17. [PubMed]
271. Telek A, Biro T, Bodo E, Toth BI, Borbiro I, Kunos G, et al. Inhibition of human hair follicle growth by endo- and exocannabinoids. FASEB J. 2007;21:3534–41. [PubMed]
272. Dobrosi N, Toth BI, Nagy G, Dozsa A, Geczy T, Nagy L, et al. Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling. FASEB J. 2008;22:3685–95. [PubMed]
273. Maccarrone M, Di Rienzo M, Battista N, Gasperi V, Guerrieri P, Rossi A, et al. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem. 2003;278:33896–903. [PubMed]
274. Paradisi A, Pasquariello N, Barcaroli D, Maccarrone M. Anandamide regulates keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent manner. J Biol Chem. 2008;283:6005–12. [PubMed]
275. Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest. 2003;111:43–50. [PMC free article] [PubMed]
276. Stander S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci. 2005;38:177–88. [PubMed]
277. Srivastava BK, Soni R, Patel JZ, Joharapurkar A, Sadhwani N, Kshirsagar S, et al. Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect. Bioorg Med Chem Lett. 2009;19:2546–50. [PubMed]
278. Ueda Y, Miyagawa N, Matsui T, Kaya T, Iwamura H. Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur J Pharmacol. 2005;520:164–71. [PubMed]
279. Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z. Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem. 2010;285:1616–26. [PubMed]
280. Braun A, Engel T, Aguilar-Pimentel JA, Zimmer A, Jakob T, Behrendt H, et al. Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB(1)/CB(2) receptors. Immunobiology. in press. doi:10.1016/j.imbio.2010.09.004. [PubMed]
281. Jan TR, Farraj AK, Harkema JR, Kaminski NE. Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice. Toxicol Appl Pharmacol. 2003;188:24–35. [PubMed]
282. De Filippis D, D'Amico A, Iuvone T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J Neuroendocrinol. 2008;20(Suppl. 1):20–5. [PubMed]
283. Li C, Bowe JE, Jones PM, Persaud SJ. Expression and function of cannabinoid receptors in mouse islets. Islets. 2010;2:293–302. [PubMed]
284. Li C, Jones PM, Persaud SJ. Cannabinoid receptors are coupled to stimulation of insulin secretion from mouse MIN6 beta-cells. Cell Physiol Biochem. 2010;26:187–96. [PubMed]
285. Gertsch J, Pertwee RG, Di Marzo V. Phytocannabinoids beyond the Cannabis plant – do they exist? Br J Pharmacol. 2010;160:523–9. [PubMed]
286. Gertsch J, Leonti M, Raduner S, Racz I, Chen JZ, Xie XQ, et al. Betacaryophyllene is a dietary cannabinoid. Proc Natl Acad Sci USA. 2008;105(26):9099–104. [PubMed]